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1. Introduction 
1.1 Malaria: A persistent public health concern 
Malaria is a vector-borne disease caused by intracellular protozoan parasites of the 
Plasmodium (P.) genus. The disease had accompanied mankind even before human 
ancestors diverged from the great apes1. Arising from its estimated origin, the Ethiopian 
areas, it followed the migration of people spreading over most of the populated parts of 
the world including Asia, North America and Europe.  
Due to global efforts within the Global Malaria Eradication Program (GMEP) of the 
World health Organization (WHO), which was mainly operating with insecticides such 
as dichlorodiphenyltrichloroethane (DDT) and anti-malarial drugs (e.g. chloroquine and 
sulfadoxine-pyrimethamine), malaria was eliminated from North America, Europe, parts 
of Asia and South America in the mid to late-twentieth century2. Despite the success in 
temperate climate zones, no major success could be achieved in the sub-Saharan region 
of Africa. Moreover, the program struggled with the economic crisis in 1970s and the 
subsequent cutting of funding for malaria control as well as the occurrence of first drug 
resistances and the restriction of DDT due to environmental and health hazards. As a 
result, the GMEP failed and malaria reappeared in many areas, and in the consistently 
malaria endemic Sub-Saharan region the death rate increased over the factor 1.51,3. 
In the early 21st century malaria was re-recognized as a serious global health issue and 
the Roll Back Malaria initiative was created. Since then eight countries have eliminated 
malaria, the global incidence and mortality have declined by 37% and 60%, respectively. 
For children under five, malaria death rates have declined by 43% worldwide4,5. This 
success was based on three key interventions: Insecticide-treated bed nets (ITN), indoor 
residual spraying (IRS) and artemisinin combination therapies (ACT). Further strategies 
comprised rapid diagnostics tests (RDT), efficient drug surveillance, strong public health 
communications and behavioral change programs6.  
Nevertheless, despite global endeavors, further progress has come to a halt and the 
number of cases per 1000 population at risk has stood at 59 for the past three years7. 
Furthermore, previous achievements are fragile as proven by the outbreak of the Ebola 
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virus in West Africa in 2014 and its devastating impact on the basic health service and 
thus on malaria control8.  
The current efforts are not sufficient to eradicate malaria and their efficacy is threatened 
to be impaired: ITN and IRS rely on a few insecticide classes particularly pyrethroids 
and emerging insecticides resistance has already covered nearly two thirds of countries 
with ongoing malaria transmission9. Further, the third key intervention, highly effective 
artemisinin-based therapies, is threatened by emerging anti-malarial drug resistance as 
further outlined in the malaria treatment section10.  
Therefore, substantial challenges in the fight against malaria remain. In 2017, there were 
still an estimated 219 million cases of malaria and 435,000 deaths worldwide7. 
1.1.1 Malaria distribution 
Malaria occurs in countries located within a belt around the tropical and subtropical 
latitudes (figure 1)11. Most of these cases occurred in the WHO African Region (200 
million or 92%). Five countries account for nearly half of all malaria cases worldwide: 
Nigeria (25%), Democratic Republic of the Congo (11%), Mozambique (5%), India (4%) 
and Uganda (4%)7. 
 
Figure 1: Countries with ongoing malaria transmission 2017, freely adapted from the country 
reports of the WHO Malaria Report 2018 7. 
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The majority of deaths concern children less than 5 years of age (78% of all deaths). 
Other vulnerable populations are malaria-naïve migrants, mobile populations, travelers 
and subjects with impaired immune system such as people infected with the human 
immunodeficiency virus (HIV), or pregnant women. Especially primigravida almost 
triples the risk of severe malaria5,12. 
The concentration of malaria cases in sub-Saharan Africa can be related to several factors 
such as meteorological condition (e.g.: precipitation, humidity and temperature), as well 
as local disease control capacities, and vector breeding preferences13. 
1.1.2 Anopheles vectors 
Malaria is a vector-borne disease transmitted by bites of feeding female Anopheles 
mosquitos. There are 512 Anopheles species recognized worldwide from which 70 are 
able to transmit Plasmodium spp. to humans14. While all Anopheles mosquitoes breed in 
water, each species has its particular breeding preferences. They differ from shallow 
transient collections of fresh water (hoof prints, irrigation ditches or puddles) to 
permanent bodies of water (swamps, or lagoons). Female Anopheles mosquitos need 
blood as a protein source for egg development. Depending on the ambient temperature, 
their eggs develop within 5-14 days into matured mosquitos. Being crepuscular or 
nocturnal, they are mainly active from dusk till dawn feeding on nectar, fruits, and other 
sources of sugar.  
Among the 512 Anopheles species 41 are defined as “Dominant Vector Species” (DVS). 
DVS are recognized as the most important malaria vectors. The Anopheles Gambiae 
complex found in Africa represent the most effective and efficient DVS. There are 4 
principal species belonging to An. gambiae complex: An. gambiae, An. arabiensis, An. 
merus and An. melas.  
1.1.3 Plasmodium species 
The malaria parasite is an eukaryotic, apicomplexan, unicellular protozoan of the 
Plasmodium genus. There are five different species known to affect humans: 
Plasmodium falciparum (P. falciparum), Plasmodium ovale (P. ovale), Plasmodium 
vivax (P. vivax), Plasmodium malariae (P. malariae), and Plasmodium knowlesi (P. 
knowlesi)15. 
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P. falciparum 
P. falciparum is the most prevalent malaria parasite in the WHO African Region 
(accounting for 99.7% of estimated malaria cases in 2017) as well as in the WHO regions 
of South-East Asia (62.8%), the Eastern Mediterranean (69%) and the Western Pacific 
(71.9%)7. P. falciparum is the focus of this thesis as it is targeted by the GMZ2 vaccine 
candidate. P. falciparum causes the most dangerous form of malaria known as malaria 
tropica. Infection with P. falciparum affects red blood cells (RBC) across all ages and 
without treatment it leads to the heaviest parasites burden. Moreover, due to the 
adherence to microvascular endothelial cells, P. falciparum can disrupt the microvascular 
blood flow and induces endothelial dysfunction. This leads, along with other factors, to 
impaired tissue perfusion16,17. P. falciparum is the main cause of severe malaria. 
P. vivax and P. ovale 
P. vivax and P. ovale are the cause of the malaria tertian, which is named after the 
characteristic fever episodes occurring every 48 hours. As result of a dormant liver stage 
called hypnozoite, they can relapse after months or years. P. ovale has typically lower 
parasitemia compared to the other Plasmodium species. It is mainly found in sub-Saharan 
Africa and the islands of the western pacific18. P. ovale consists of two species (P. ovale 
curtisi and P. ovale wallikeri)19. P. vivax has a broader distribution due to sporogonic 
development at lower temperatures. However, it is limited in Africa due to the absence 
of the required duffy receptor on RBC in many African populations. Despite the 
historical name “benign tertian malaria”, P. vivax infection has a substantial burden of 
disease. Even if it is less virulent compared to P. falciparum, it induces similar anemia, 
which can lead severe illness and fatal outcomes particularly when associated with co-
morbidities20,21.  
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P. malariae 
P. malariae induces malaria quartana with fever episodes occurring every 72 hours. Its 
distribution coincides at large with P. falciparum. The prepatent period is wide ranged 
from 16 to 59 days and extended compared to the other plasmodia (6-27 days). The 
prolonged fever cycle, targeting of elder erythrocytes in the blood-stage and the lower 
amount of merozoites per infected red blood cell (iRBC) leads to comparative lower 
maximum blood parasites densities. P. malariae does not relapse from dormant liver 
stages, nevertheless it can persist for an extensive period in the blood at very low 
densities and recrudesce after decades. Moreover, malaria quartana can cause the 
nephrotic syndrome22. 
P. knowlesi 
P. knowlesi is mainly found in Southeast Asia. It was first described in infected macaques 
in 1931 and not till 1965 reported as a naturally acquired human infection due to 
difficulties distinguishing it from other plasmodia by microscope. By now, there is no 
evidence of man-to-man transmissions and therefore the disease is considered zoonotic. 
Nevertheless, P. knowlesi poses a threat in forested areas in Southeast Asia23. 
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1.1.4 Life cycle and pathophysiology 
The life cycle of the Plasmodium parasite is complex and features altering intra and extra 
cellular life stages in both vertebrate and arthropod hosts (figure 2). 
 
Figure 2: Life cycle of plasmodia, Center of Disease Control (CDC) 24.While feeding on the 
human host, the infected mosquito inoculates motile sporozoites. They actively navigate through 
the skin in pursuit of a capillary vessel to be flushed into the liver [1]. After 15-45 min, they 
invade hepatocytes [2], remain there for 9-16 days maturing into schizonts [3] and undergo exo-
erythrocytic schizogony (A). During this stage, P. vivax and P. ovale can develop dormant liver 
stages (hypnozoite). With the rupture of the liver cell 2000-30,000 merozoites are released [4], 
which actively infect RBCs [5] and initiate the erythrocytic schizogony (B). The now called 
trophozoites develop into schizonts, which releases 8-32 merozoites by rupture [6], which 
continue the cycle by re-infecting further RBCs. This leads to an approximately ten-fold increase 
of iRBC every 48 hours. The feed-forward loop with exponential multiplication continues until 
limited by metabolic resource-restriction, the immune system, or anti-malarial treatment. The 
parasitemia can built up to 1013 parasites, which causes the clinical symptoms25. A small fraction 
of the merozoites develop into longer living sexual forms (gametocytes) [7], which are ingested 
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by a blood meal taking anopheles mosquito [8]. The sexual proliferation in the mosquito is called 
sporogonic cycle (C). In the gut of the mosquito the gametocytes are released from the 
erythrocytes. The microgametes (male form) fertilizes the macrogametes (female form) forming 
zygotes [9], which develop into motile ookinetes and encysts in the midgut wall of the mosquito 
[10, 11]. By mitosis and meiosis thousands of haploid sporozoites are created and released 
during the rupture of the mature oocyst [12]. After migrating to the salivary glands, the 
sporozoites finish their differentiation and await inoculation into the next human host during a 
subsequent mosquito bite [1]. 
 1.1.5 Immune response to P. falciparum  
Plasmodium spp. are immune-evasive parasites exerting high antigenic variation 
throughout their life cycle26,27. The response of the human immune system is an equally 
complex interplay of the native and adaptive system as shown in figure 3. It consists of 
humoral and cellular immune response including antibodies, cytokines, regulatory and 
effector T cells, neutrophil and monocyte activation28. However, the specific 
mechanisms mediating these immune cascades remain poorly understood29 and sterile 
immunity is typically not achieved30. 
Thousands of years of co-evolution between the parasite and the human host have 
induced an immense evolutionary pressure exerted by the human immune system. This 
has selected for an extensive polymorphism of parasite genes encoding immunodominant 
antigens, known as antigenic variation31–33, whereas the functionally relevant and 
conserved protein regions of the genes are often poorly immunogenic, which subsequent 
leads to immune evasion34. Most antigens of the sporozoite, liver and sexual blood-stage 
are rather conserved, compared to antigens of merozoite and surface of iRBCs, which 
are extremely polymorphic31. Furthermore, evidence suggests that parasites can also 
effectively modulate the host immune system35,36. This permits reinfections and the 
potential chronic character of the disease30,32. A fragile equilibrium between pro-
inflammatory and regulatory responses affects the outcome of an infection37 and has been 
proposed as target for immune-modulatory interventions38. 
Naturally acquired immunity (NAI) can develop following repeated infections. It is 
robust but usually not sterile and titled semi-immunity in the malaria field. It requires 
recurrent infections over a prolonged period, depends on the degree of exposure, and can 
be further subdivided into: (I) A rather rapidly acquired anti-disease immunity which 
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impairs the chance of severe clinical outcome within a same level of parasitemia; (II) A 
relatively slower developed anti-parasite immunity, which diminishes parasite densities 
and therefore alleviates the clinical symptoms.  
One possible mechanistic model for the development of NAI is called premunition, 
where chronic low grade asymptomatic parasitemia is proposed to protect from severe 
clinical outcomes of new infections30,39. However, one remains susceptible for malaria 
infections and if the reinfection rate falls below a certain threshold, the protection wanes 
over time. The anti-disease immunity has an estimated half-live of 5 years whereas the 
slower acquired antiparasitic immunity has an estimated half-life of 20 years30.  
Humoral immunity  
Antibodies are related to protection as several passive transfer studies in humans have 
shown since 196040–42. The humoral immune response to malaria is mainly characterized 
by immune-globulin (Ig)-G, whereas the roles of the other immunoglobulin classes like 
IgM, IgA and IgE are not well described43. Antibodies can be effective (e.g. inhibiting), 
neutral or contra productive due to blocking of effective antibodies. In the latter case, 
they can even have a negative effect44. The protection of IgG is mainly mediated by the 
cytophilic subclasses IgG1 and IgG345. At the pre-erythrocytic life stage antibodies can 
immobilize and opsonize the inoculated sporozoites until they invade hepatocytes46. 
During the intracellular hepatic stage, the parasite is not targetable by antibodies. 
Throughout the subsequent erythrocytic stage merozoites-specific antibodies are likely 
to play an important role. They agglutinate and opsonize the parasite, which leads in 
cooperation with effector cells to phagocytosis, complement mediated damage44, 
prevention of further RBC invasion47 and Antibody-Dependent-Cellular-Inhibition 
(ADCI). This is further boosted by lymphocytes, which produce interferon γ (IFN-γ) and 
subsequently activate macrophages. Further important antibodies target antigens of 
infected RBCs and inhibit their sequestration in capillary vessels. 
Cellular immunity  
Once the sporozoites reach the liver and invade hepatocytes, they are concealed against 
antibody targeting. Hence, the now intracellular parasite is targeted by the cellular part 
of the immune system. The major role play CD8+ T cells, which start immune cascades 
including CD4+ T cells, natural killer cells, interleukin(IL)-12, IFN-y and NO as final 
 
- 9 - 
 
effector44. Moreover, CD4+ T cells can have a major impact on the nature of the over-all 
immune response depending on their predominant subset. Subsets are characterized by 
their distinct chemokine secretion profiles and their different expression of surface 
receptors48. Balance between inflammatory and non-inflammatory immune responses 
appears to be key for the clinical outcome of a malaria episode49. A strong early TH1-
mediated pro-inflammatory answer is needed to reduce parasite growth and facilitate the 
clearance of iRBCs, whereas an unregulated excessive response may lead to 
immunopathology and severe malaria31. 
 
 
Riley and Stewart 2013, Figure 2 
Figure 3: Immune response against malaria. Parasites or iRBCs are recognized by dendritic 
cells (DC) through pattern recognition receptors (PRRs). This leads to phagocytosis and 
subsequent presentation of pathogen-antigens to T cells. Depending on the signaling of the PRR, 
cytokines are secreted, which direct the T cell differentiation, cause the inflammation and 
malaria pathogenesis. TH1 cells support B cell maturation and antibody production. Moreover, 
they activate macrophages through IFN-γ secretion. Activated macrophages in turn phagocytose 
opsonized parasites and release proinflammatory cytokines. Endothelial cells express adhesion 
molecules, which bind infected RBC. The restoration of immune homeostasis is induced by anti-
inflammatory cytokines secreted by regulatory T cells (Treg) and makrophages
31. Reprinted with 
permission from Nature Publishing Group. 
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1.1.6 Clinical appearance 
Uncomplicated malaria 
After a clinically silent incubation period of approximately 14 days (up to 4 weeks for P. 
falciparum) P. falciparum infection can result in a range of symptoms going from minor 
to severe and potentially fatal. A typical sign of malaria is the appearance of fever. Its 
frequency is related to the erythrocytic schizogony. During the synchronized rupture of 
infected RBC, accumulated parasite products like hemozoin are released into the 
bloodstream. This induces an immune response triggering fever, rigor and other 
inflammatory responses related to malaria. Characteristically this ague occurs every 48 
hours with malaria tertiana and every 72 hours with malaria quartana. Malaria tropica 
however demonstrates irregular fever attacks due to less synchronized erythrocytic 
schizogony. Even though a three-stage progression of disease (cold, hot and sweating 
stage) is called classic, it is rarely observed. More common is a combination of symptoms 
such as: Fever, chills, fatigue, headaches, perspiration, myalgia, nausea, vomiting, cough 
general malaise and abdominal discomfort. Physical examination may reveal an enlarged 
spleen, mild jaundice as well as an enlargement of the liver. Characteristic but not 
obligatory is a decreased platelet (plt.) count, elevated total bilirubin and lactate 
dehydrogenase (LDH) 17,50,51. Additional findings may occur depending on the progress 
of the disease and the extend of organ dysfunctions. If not treated properly at this stage, 
the parasite burden may increase and complications occur within days or even hours 
depending on the virulence of the pathogen and the susceptibility of the host17,50,52,53.  
Severe malaria 
Even though infections with P. vivax and knowlesi can result in severe malaria, P. 
falciparum is responsible of the vast majority of severe malaria cases51. Severe malaria 
is defined by clinical or laboratory evidence of vital organ dysfunction in the absence of 
an identified alternative cause, and in the presence of P. falciparum asexual 
parasitaemia51,52,54. Several definitions are used for the classification of severe malaria. 
The WHO classifications, which are most frequently used, have been developed for 
bedside classification of patients living in high transmission settings, where diagnostics 
rely mainly on clinical signs and symptoms. Along with this classification the WHO also 
proposed an epidemiologic and research definition of severe P. falciparum considering 
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both clinical and laboratory findings (table 1). It shall be noted that untreated severe 
malaria has a very high risk of death. Immediate anti-malarial treatment and intensive 
care can reduce this mortality rate to <10%51. 
Table 1: Epidemiological and research definition of severe falciparum malaria 51 
Impaired 
consciousness: 
A Glasgow Coma Score <11 in adults or a Blantyre coma score <3 
in children 
Acidosis: A base deficit of >8 meq/l or, if unavailable, a plasma bicarbonate 
of <15 mM or venous plasma lactate >5 mM. Severe acidosis 
manifests clinically as respiratory distress – rapid, deep and labored 
breathing 
Hypoglycemia: Blood or plasma glucose <2.2 mM (<40mg/dl) 
Severe malarial 
anemia: 
A hemoglobin (HGB) concentration <5 g/dl or a hematocrit of 
<15% in children <12 years of age (<7 g/dl and <20%, respectively, 
in adults) together with a parasite count >10 000/μl 
Renal impairment 
(acute kidney injury): 
Plasma or serum creatinine >265 μl (3mg/dl) or blood urea >20 mM 
Jaundice: Plasma or serum bilirubin >50 μl (3mg/dl) together with a parasite 
count >100,000/μl 
Pulmonary edema: Radiologically confirmed, or oxygen saturation <92% on room air 
with a respiratory rate >30/min, often with chest indrawing and 
crepitations on auscultation 
Significant bleeding: Including recurrent or prolonged bleeding from nose gums or 
venipuncture sites; hematemesis or melaena 
Shock:  Compensated shock is defined as capillary refill ≥3 s or temperature 
gradient on leg (mid to proximal limb), but no hypotension. 
Decompensated shock is defined as systolic blood pressure <70 mm 
Hg in children or <80 mm Hg in adults with evidence of impaired 
perfusion (cool peripheries or prolonged capillary refill) 
Hyperparasitemia P. falciparum parasitemia >10% 
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Asymptomatic P. falciparum infections  
Asymptomatic P. falciparum infections occurs especially in areas with stable malaria 
transmission where semi-immune individuals can carry asymptomatic chronic infections 
with low parasitemia over prolonged periods of time. Even though this infection does not 
pose a real threat, they constitute an important reservoir of parasites under the radar of 
the health system. This subsequently enhances the local transmission and poses another 
obstacle to malaria elimination55,56. 
1.1.7 Laboratory diagnostic 
The spectrum of malaria symptoms is wide ranged and has no clinical pathognomonic 
characteristics. Malaria diagnosis is supported by fever, or history of fever in absence of 
any other obvious cause. Because of the difficulties to distinguish clinically between 
malaria and other potential causes of fever, different diagnostic methods can be applied. 
The gold standard under field conditions is the conventional bright field microscopic 
examination of a thick blood smear (TBS). There are further microscope based diagnostic 
tools such as the quantitative buffy coat method and the Partec Rapid Malaria Test. 
Moreover, different RDTs and a variety of molecular diagnostic methods complement 
the diagnostic arsenal57. 
Microscopic based diagnosis 
Thick blood smear 
The gold standard of malaria diagnosis is the microscopic examination of Giemsa-stained 
TBS. It is cost effective, requires just a small volume of blood, can differentiate malaria 
species, and quantify parasites with a lower limit of detection of 10-100 parasites/μl 
(depending on the experience of the laboratory staff). Therefore, it is the most commonly 
used test in endemic countries. Nevertheless, it relies on the expertise of the reader, the 
quality of the prepared blood slide and the condition of the microscope53,57. 
Quantitative buffy coat method 
Fluorescence microscopes are used to detect acridine orange stained parasites in 
centrifuged blood. It has a better sensitivity with 5 parasites/μl and requires less trained 
personal. However, it is unable to differentiate between species and specific equipment 
is required57.  
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Partec Rapid Malaria Test 
Prelabelled malaria slides bind intraerythrocytic Plasmodium DNA, which can then be 
visualized under a fluorescence microscope (Partec CyScope®). It is fast, easy to use, 
requires less experienced personal and due to rechargeable batteries, it is suitable for 
settings without electric supply. Drawbacks are the specific equipment, difficulties in 
species differentiation and false positive results57. 
Rapid diagnostic tests 
RDTs use immune-chromatographic assays with monoclonal antibodies directed against 
the target parasite antigen. Results can be obtained within 5- 20 min via a colored test 
line. Most commonly used RDT only detect P. falciparum, but there are already 
advanced tests available, which distinguish between species. Disadvantages result from 
the relatively high threshold of 200 parasites/μl, false negative results in presence of high 
parasitemia (>10%), high costs and variable test result reliability in different 
environmental conditions. Furthermore, the most commonly used antigen for the RDTs 
is histidine-rich protein 2, which can be absent in some wildtype parasite strains leading 
to false-negative results as indicated by recent reports58. Therefore, RDTs are limited to 
situations, when high quality microscopy is unavailable 59. 
Polymerase chain reaction 
Molecular diagnostic tools such as Polymerase chain reaction (PCR) play an important 
role in scientific settings to detect resistances, mixed infections, low parasite densities 
(Up to 0.02 parasites/μl), or asymptomatic carriers. PCR requires highly trained personal, 
rigorous laboratory sterility, high costs and is relatively time consuming. Therefore, it is 
not suited for the clinical management of malaria especially in remote areas53,57. 
Non-invasive tests 
Further methods are in the developing pipeline, such as biomarkers in human breath, 
urine malaria tests, or transdermal laser detection of malaria parasites. While these 
methods are still in their infancy, they yield promising results to serve as future 
alternative malaria diagnostic tools57.  
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1.1.8 Current treatment options  
There are a limited number of drugs available to treat or to prevent malaria. They are 
derived from a restricted set of chemical compounds, which according to WHO 
classification, can be grouped into 6 categories: 
• Quinine and related compounds 
• Antifolate combination drugs 
• Antibiotics 
• Artemisinin compounds 
• Miscellaneous compounds (not exhaustive) 
• Combination therapy with antimalarials53 
 
Uncomplicated malaria  
Uncomplicated malaria (excluding infection during first trimester pregnancies) is treated 
with ACT. In areas of low transmission, an additional single dose of primaquine is 
recommended53. Pregnant women in their first trimester are treated with quinine in 
combination with clindamycin. Primaquine is one of the few drugs targeting gametocytes 
and thus reducing transmission. Moreover, it provides radical cure from P. ovale and P. 
vivax by clearing hypnozoites and preventing relapses60. However, primaquine may 
cause fatal hemolysis in people with glucose-6-phosphate dehydrogenase (G6PD) 
deficiency, which is common in malaria-endemic regions61.  
Severe malaria 
For treatment of severe malaria, intravenous or intramuscular artesunate for at least 24 
hours is recommended. If parenteral artesunate is not available, artemether is used in 
preference to quinine. Afterwards, if oral therapy is tolerated, the three days regime is 
completed with an oral ACT53. 
Chemoprophylaxis  
Non-immune travelers visiting malaria endemic areas can be protected by 
chemoprophylaxis. Especially individuals, who are backpacking or staying overnight in 
rural areas, are particularly at risk. Atovaquone-proguanil is the most commonly used 
drug combination for chemoprophylaxis62.  
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1.1.9 Current status of anti-malaria drug efficacy 
Resistances to anti-malarial drugs have been described for two out of the four species of 
malaria parasite that naturally infect humans - P. falciparum and P. vivax7. 
The first safe, effective and affordable anti-malarial drug was chloroquine. It dominated 
anti-malaria therapy for over two decades. Following a massive monotherapy strategy 
with chloroquine, development of resistance started to be reported in several areas and 
spread across Africa in the 1980s leading to a dramatic resurgence of malaria including 
malaria-related deaths. Today, about 80% of wild isolates are resistant to chloroquine63. 
Although chloroquine is not used in most countries anymore, it remains first line 
treatment in the Dominican Republic, Guatemala, Haiti, Honduras and Nicaragua7. And 
due to structural modifications, derivates such as amodiaquine and ferroquine64 are still 
part of anti-malarial treatment regimens65.  
Today, emerging drug resistances to newer drug classes are threatening their utility, 
too10. Current most effective and rapid acting anti-malarial drugs are artemisinin 
derivates. To prevent the emergence of resistance by selection of resistant parasite 
strains, artemisinin is used only in combination with other anti-malaria drug classes, 
which feature a prolonged half-life. This allows the longer acting partner drug to clear 
residual parasites, which were not eliminated by artemisinin derivates and therefore limit 
the selection for resistant parasites strains10. Despite these efforts, current treatment 
options are seriously threatened by emerging of strains with decreased artemisinin 
sensitivity reported from the Thai-Cambodian border66,67 and lately also from the Thai-
Myanmar border68,69.  
The WHO constantly monitors the efficacy of anti-malarial drug and has established a 
global database on anti-malarial drug efficacy and resistance containing data on 
therapeutic efficacy studies for P. falciparum and P. vivax and, more recently, data from 
studies of molecular resistance markers7. Based on the analysis of available data it has 
been noted that the efficacy of ACT currently recommended in national malaria treatment 
policies remains effective with overall efficacy rates of greater than 95%. Nevertheless, 
it is uncertain if the ACTs will remain effective in the future.  
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1.2 Vaccine development against P. falciparum  
The current arsenal of malaria control tools may be sufficient to eliminate the disease in 
low transmission areas and reduce morbidity and mortality in areas of high transmission, 
but they are not adequate to eradicate malaria70. Therefore, new tools and innovations 
are needed and a malaria vaccine has tremendous potential for malarial elimination even 
in high endemic transmission areas70,71. Vaccines have proven to be the most cost 
effective and efficient intervention for public health72. They have been utilized in several 
previous eradication programs such as polio73, smallpox74 and measles75. Because of the 
expected potential of a malaria vaccine in the fight against malaria, in 2015 the global 
health community has called for the development and licensing by 2030 of malaria 
vaccines with protective efficacy of at least 75%70. 
1.2.1 Classification of malaria vaccine candidates 
The first preclinical approaches for a malaria vaccine began in the 1930s34. Four decades 
later Clyde et al. immunized malaria naïve individuals for the first time using irradiated 
P. falciparum sporozoites inoculated via mosquito bite76. Given the difficulty to 
reproduce this method at a large scale and particularly for mass vaccination, it was 
abandoned. The technological advance observed during the same period allowed the 
development and a switch to protein based sub-unit malaria vaccine candidates34. Despite 
decades of research, a highly efficient, long lasting anti-malarial vaccine remains elusive. 
By now, over 5,000 potential P. falciparum antigens were isolated and more than 40 
malaria vaccine candidates were tested in clinical studies from phase I to III. The current 
pipeline of clinical development is displayed in figure 4.  
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Figure 4: Global malaria vaccine pipeline created with the data of the WHO malaria vaccine 
rainbow tables (last updated 17 July 2017) 77 
Based on the stage of the Plasmodium spp. lifecycle they target, malaria vaccine 
candidates can be divided into four different categories: pre-erythrocytic, blood-stage, 
transmission blocking vaccines or multistage vaccines (figure 5). Although most of these 
vaccines are made out of recombinant protein with antigenic properties, also live 
attenuated whole sporozoites vaccines have witnessed a renewed interest78. 
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Riley and Stewart 2013, Figure 3 
Figure 5: Malaria vaccine approaches: Aims and required immune responses. Pre-erythrocytic 
vaccines intercept parasites before they can reach the blood. They target sporozoites with AB 
and infected hepatocytes with cytotoxic T cells. This approach aims at sterile protection. In 
contrast, the blood-stage vaccine acts upon parasites in the asexual and sexual blood stage 
mainly relying on high titers of AB. While not necessarily offering sterile protection, this 
approach aims at alleviating clinical symptoms and allowing the development of NAI. Whereas 
the transmission targeting vaccines prevent parasite development within the mosquito using AB 
against gametocytes, gametes and ookinetes. This last approach does not protect the individual 
from clinical malaria, however it prevents transmission and therefore provides protection on a 
community level. Combination multistage vaccines act on different stages trying to combine the 
strengths of the singular approaches. TEM, effector memory T cells; TCM, central memory T 
cells. Reprinted with permission from Nature Publishing Group31. 
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Pre-erythrocytic vaccines 
Live attenuated whole sporozoites vaccine 
The rationale for this approach is rooted in historical studies conducted in the 1910s 
showing that immunization of animals with irradiated sporozoites can lead to protective 
immunity79. Translation of these findings were made in human in the 1970s, when human 
subjects were immunized for the first time by irradiated sporozoites against homologous 
strains of P. falciparum. In this approach the inoculation of parasites was done by the 
bite of over 1000 infectious mosquitos76. Irradiated sporozoites are metabolically active 
but incapable of completing their life cycle and stay blocked in hepatocytes where they 
die before reaching the blood. As a consequence, immunized participants do not develop 
malaria and the immune system is exposed to sporozoites and infected hepatocytes 
presenting parasite-derived peptides on MHC class I molecules. This induces immune 
responses to many different epitopes at the same time and subsequently limits the 
negative effect of antigenic polymorphism and immunological non responsiveness, 
which is the main obstacles in developing subunit vaccines especially blood-stage 
vaccines78. Despite the promising result obtained during first in human trials, clinical 
development of live attenuated sporozoites vaccines stopped as it was deemed 
impractical to use for a malaria control program. Nevertheless, more recently a major 
breakthrough was made by the production of aseptic, purified and vialed P. falciparum 
sporozoites by SANARIA which can be inoculated intravenous to potential recipients80. 
Several clinical trials have been or are currently conducted to assess the tolerability 
profile and the efficacy of live attenuated whole sporozoites vaccines in Europe and 
Africa. Overall, they show that life attenuated sporozoites vaccines are generally safe 
and can reach 80-100% efficacy in homologous vaccine and challenge trials80.  
Of note, vaccine efficacy was much lower (30-50%) in semi-immune study subjects 
under natural exposure81. Reasons for the lower efficacy are currently under 
investigation. Moreover, large-scale production according to good manufacturing 
practices, transportation and storage in liquid oxygen are still posing obstacles. Further 
research has to conclude, whether these obstacles can be overcome. 
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Besides the use of irradiation, Plasmodium spp. sporozoites can also be attenuated 
through genetic modification or by chemoprophylaxis in a course of Plasmodium spp. 
sporozoites inoculation.  
Recombinant pre-erythrocyte malaria vaccine 
Among the recombinant pre-erythrocyte malaria vaccines RTS,S has been the most 
promising. It is the only malaria vaccine candidate reaching a phase III efficacy trial. 
Result of this phase III trial indicated a good tolerability profile and an efficacy ranging 
from 20 to 40%82. The vaccine received a positive scientific opinion by the European 
Medicines Agency in 201583 and was recommended by the WHO for a pilot 
implementation program in Africa, which is currently ongoing in Ghana, Kenya, and 
Malawi84. RTS,S was engineered using genes from the pre-erythrocytic 
circumsporozoite protein (CSP) of the P. falciparum malaria parasite and a viral 
envelope protein of the hepatitis B virus (HBsAg) adjuvanted with AS01. Infection is 
prevented by inducing humoral and cellular immunity with high antibody titers blocking 
the parasite from infecting the hepatocytes. Other pre-erythrocytic recombinant malaria 
vaccines have been or are currently under clinical development but none has provided 
considerably better results.  
Present pre-erythrocytic approaches may diminish, but not eliminate, the risk of 
infections with P. falciparum. Reaching an efficacy of up to full protection in a malaria 
endemic setting remains elusive. That leaves the fraction of immunized population at 
risk, where, despite immunizations, P. falciparum slips through pre-erythrocytic 
protection, and reaches blood-stage. Without a blood-stage immunity, a parasite reaching 
blood-stage is likely to induce clinical malaria infection. Moreover, any intervention with 
partial efficacy bears the risk of a rebound effect as it slows down the development of 
NAI as demonstrated with RTS,S85. This indicates that any malaria vaccination approach 
aiming at minimizing long-term morbidity and mortality should ideally implements a 
blood-stage component to control the erythrocytic schizogony.  
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Asexual blood-stage vaccines 
Asexual blood-stage vaccines (BSV) aim to directly reduce malaria morbidity and 
mortality since the clinical features of the disease are caused by the asexual erythrocytic 
schizogony. The feasibility of immunization with Plasmodium spp. blood-stage antigens 
is rooted in the observation, that the NAI to the parasite is partly mediated by 
immunoglobulin against blood-stage Plasmodium spp. antigens. It was demonstrated that 
the transfer of serum of lifelong malaria-exposed immune adults could be used 
therapeutically to ameliorate disease symptoms and control parasite density of malaria 
patients40,41. However, the identity or pattern of the protective immunoglobulin is still to 
be determined, since during the blood-stage the immune response to the parasite appears 
to be complex and a vast variety of epitopes are expressed35. In general, a suitable antigen 
to be incorporated in a BSV candidate should elicit a sufficient immune response, while 
being conservative enough to cover an adequate number of genetically distinct parasite 
strains in order to be efficacious and minimize the risk of inducing vaccine escape 
mutants. It is highly likely that the vaccine-induced immunity could be boosted by natural 
infection, and therefore maintained naturally over a long period of time. While not 
inducing sterile immunity, it subsequently allows the development of NAI. Therefore, a 
BSV may not only be used as stand-alone product, but also in combination with a pre-
erythrocytic vaccine in a sense that any parasite, which was not neutralized through the 
pre-erythrocytic immunity would be targeted by the BSV. 
The current repertoire of BSV is made of recombinants of Plasmodium spp. proteins. A 
leading candidate of the group of asexual blood-stage, GMZ2, has shown to be most 
promising and has reached a phase IIb multi-center trial. 
Malaria transmission-blocking vaccine  
Malaria transmission-blocking vaccines (TBV) primarily aim to reduce malaria 
transmission by interrupting the sexual, and sporogonic stage of the parasitic life cycle 
within the mosquito. Unlike pre-erythrocyte and BSV, TBV do not prevent infection, 
reduce parasite load or prevent the disease in its recipient86. However, by stopping 
Plasmodium spp. transmission, TBV have the potential to reduce malaria morbidity, 
decrease the size of the parasite human reservoir and may even lower the basic 
reproductive number below one, leading to local malaria elimination87. The use of TBV 
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in combination with an anti-malarial drug (i.e. in mass drug administration programs), or 
TBV antigens as a component in a multivalent vaccine could also help to contain the 
occurrence of drug and potential vaccine resistances88. From an evolutionary perspective, 
the selection pressure exerted on the parasite during its mosquito stage is thought to be 
lower than during the human development life cycle. As a consequence, it is assumed 
that Plasmodium spp. sexual stage antigens are less polymorphic making it easier to 
develop vaccines which exert cross-species immunity 34,89. There are currently few 
antigens with the potential to be used or being used for the development of TBV. So far, 
only a limited number of TBV candidates are currently under clinical development 
(AnAPN1, Pfs230, Pfs48/45, Pfs25)86. A clinical phase I study regarding the most 
advanced TBV candidate Pfs25 shows promising results, while also raising safety 
issues89.  
Multistage malaria vaccines 
Combining pre-erythrocytic, erythrocytic and even TBS give the advantage of targeting 
multiple stages of the parasite life cycle. In this approach blood-stage antigens are to 
induce an immune response targeting parasites, which could not be neutralized by the 
protection induced by pre-erythrocytic immunization90. This can give the advantage of 
limiting vaccine resistance. Downsides of multistage malaria vaccine exist and are 
mainly associated with an increase in manufacturing costs91 and possible antigen 
interference leading to diminished immune responses against individual antigens92. 
Vaccines against pregnancy-associated malaria (PAM) 
Especially during primigravidae women are prone to malaria, as already described in 
section 1.1.1 (Epidemiology). The rapid reestablishing of NAI during subsequent 
pregnancies indicates a specific immune mechanism for PAM93. The sequestration of the 
erythrocytes to maternal side of the syncytiotrophoblast is mediated by VAR2CSA, a 
conserved variant of P. falciparum erythrocyte membrane protein 1 (PfEMP1). The titer 
of anti-VAR2CSA antibodies correlates with reduced risk of delivering low-birthweight 
babies94. This subsequently has led to PfEMP1 as the first vaccine candidate for PAM in 
preclinical development34,95. 
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1.2.3 GMZ2: A blood-stage malaria vaccine 
GMZ2 targets the asexual blood-stage and is a recombinant fusion protein containing 
fractions of P. falciparum antigens. The N-terminal non-repeat region of the glutamate-
rich protein (GLURP-R0, amino acids 27-500) is fused to the C-terminal region of 
merozoite surface protein 3 (MSP3, amino acids 212-380) and expressed in Lactococcus 
lactis96. The production system with Lactococcus lactis was chosen, because the gram 
positive bacterium is well described, has been consumed by humans for centuries, has 
low immune stimulation potential, does not produce endotoxins, and can efficiently 
secrete GMZ2 into the culture supernatant96. Endogenous GLURP27-500 is a 
conservative97 major B cell epitope expressed in the pre-erythrocytic and erythrocytic 
stage98. MSP3212-380 is a conservative part of the otherwise highly polymorphic 
MSP399,100. It is one of the first vaccine candidates identified by analyzing therapeutic 
immunoglobulin preparations41,101 and immune-epidemiological correlations studies102. 
GMZ2 itself is a sufficient presentation of epitopes of GLURP and MSP3 and elicits 
higher immunogenicity compared to the administration of the single protein MSP3 or 
GLURP96. 
Immuno-epidemiological studies 
There are several BSV candidates in clinical development. However, the majority of 
studies conducted so far have shown disappointing results. Either the protection induced 
by the vaccine candidate is too low (falciparum malaria protein 1, MSP1103, Apical 
membrane antigen 1 (AMA-1)104), or it is limited to the vaccine strain (MSP1 and MSP2, 
ring-infected erythrocyte surface antigen (RESA)105, AMA-1106). Among the known 
repertoire of antigens expressed by the parasite during the blood-stage, MSP3 and 
GLURP are deemed as promising vaccine candidates. This is mainly based on 
epidemiological and laboratory data indicating an association between MSP3 and 
GLURP antibody levels and clinical protection against malaria101,107–110. Indeed, 
individuals in malaria endemic countries develop antibodies against MSP3 as well as 
GLURP110 under natural infection. These antibodies seem to play an important role in 
NAI and are associated with protection109,111,112. This later observation is of particular 
interest, as it suggests that vaccination with GMZ2 cannot only induce protection but 
may also be boosted by natural infection.  
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Although the mechanism of protection to P. falciparum elicited by the vaccine is not yet 
fully understood, it has been shown that the vaccine induce specific cytophilic IgG1 and 
IgG3 are associated with protection against malaria
109,111. Evidence indicates that vaccine 
specific antibodies can also mediate opsonic phagocytosis of merozoites by binding Fcγ-
receptors of neutrophils. If FcγRIIA and FcγRIIIA receptors on monocytes are activated 
by cross-linked IgG bound to parasite antigens, soluble factors are released and ADCI is 
initiated. This appears to be the predominant effector mechanisms rather than direct 
growths inhibition42,113–116. Among all proposed surrogate markers considered, ADCI is 
the method showing the closest association with clinical protection117 and is an accepted 
method to validate vaccine candidates118. GLURP119, MSP3101, and GMZ2118 have 
shown to induce good ADCI reactions. Especially cytophilic MSP3 antibodies have a 
strong capacity to induce ADCI120. 
Pre-clinical assessment  
GMZ2 has been evaluated in several pre-clinical studies. GMZ2 immunized mice 
showed higher levels of anti-GLURP and MSP3 compared to mice injected with single 
GLURP, MSP3 or both antigens96. Moreover, an in vitro parasite-growths inhibition was 
demonstrated using mouse anti-GLURP-MSP3 IgG in cooperation with human 
monocytes96. The tolerability, immunogenicity and efficacy were further evaluated 
during a study in Saimiri sciureus monkeys. The study achieved partial protection with 
GMZ2 upon challenge with P. falciparum and demonstrated that anti-GMZ2 IgG can be 
boosted by challenge 108. This indicates that the vaccine protection might be boosted by 
natural infection. 
Clinical development 
The first-in-man phase I trial clinical study in healthy malaria naive adults took place in 
Tübingen in 2006 to access safety, tolerability, and immunogenicity in humans. Since 
the study was successful121, the next trial moved from malaria naïve participants to semi-
immune adults. This was done to access whether the results can be reproduced in a 
malaria endemic surrounding. The phase I trial in Gabon in 2007 confirmed the good 
tolerability profile and proved that the pre-existing immune response can be boosted122. 
Consequently, the development proceeded to the target population of healthy African 
children (2008). While achieving promising results, the study had not the power to access 
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vaccine efficacy123. Thus, a large phase IIb multicenter study in Ghana, Burkina Faso, 
Gabon and Uganda was conducted in 2010. Although the study showed a good 
tolerability profile and robust immunogenicity, the vaccine efficacy with 13.6% (95% 
CI: 3.6%, 23%) was to low compared to what is required for a substantial impact124. 
However, at all study sites vaccine efficacy was similar, suggests a pan-reactive vaccine, 
which is not limited by strain specific immunogenicity. Moreover, a significant 
relationship between the immunogenicity and vaccine efficacy could be established. This 
indicates, that another GMZ2 formulation, which elicits higher antibody titers could 
significantly increase vaccine efficacy.  
During the pre-clinical studies GMZ2 was adjuvanted with different types of adjuvants, 
which had a high impact on the level of antibodies elicited108. This led to the assumption 
that GMZ2 given with a different adjuvant could still meet the requirement of the 
preferred product profile of the WHO for malaria vaccine125. 
 
Figure 6: Clinical trials of GMZ2 
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Adjuvant selection 
Many subunit vaccines require an adjuvant to be immunogenic. While most malaria 
vaccine trials used to start with aluminum salts as the adjuvant, evidence rises that 
especially subunit vaccines need a more potent delivery system to be successful. A good 
adjuvant preserves the conformational integrity of the vaccine antigen and delivers it to 
immune effector cells. There, it presents the vaccine antigen at a bigger size or other 
mechanisms that induce a response that facilitates the recognition and uptake through 
antigen presenting cells (APC). Simultaneous activation of distinct PRR of the same APC 
induces a higher proinflammatory response and the upregulation of necessary 
cytokines126. This subsequently leads to a stronger initiation of innate and often to a better 
adaptive immunity. Additionally, an adjuvant generates a depot of antigen and can 
mediate prolonged and controlled release of antigens supporting long-lasting immune 
responses47. Further, it influences not only the magnitude of elicited immunogenicity but 
also the avidity of antibodies and can broaden the vaccine response against heterologous 
pathogen strains127. Different adjuvants elicit distinct immune responses depending on 
the evoked cytokines and on promoted T-helper (TH) cell subsets.  
Alhydrogel, an aluminum hydroxide suspension, was chosen in previous GMZ2 trials 
because of its good tolerability profile, since the final target population of a blood-stage 
malaria vaccine are children in Sub-Saharan Africa. It is one of the most common, cost-
effective adjuvants, already used for over 80 years and has an extensive track record of 
safety and tolerability128. The downside is the inability to induce a TH1 immune profile 
promoting INF-γ, and IL-12, which appears to be crucial for protection against 
malaria129,130. Moreover, in a pre-clinical study was shown, that GMZ2 combined with 
Alhydrogel elicited lower antibody response than combined with different 
adjuvants108,131. Furthermore, the leading malaria vaccine candidate RTS,S showed little 
efficacy when adjuvanted with Alhydrogel132. 
These observations motivated to change the type and nature of adjuvant used for the 
GMZ2 vaccine and to investigate a formulation with the Cationic adjuvant formulation 
01 (CAF01). CAF01 is developed by Statens Serum Institut and contains two 
components: dimethyldioctadecylammonium (DDA) cationic liposomes and α,α’-
trehalose 6,6’- dibehenate (TDB). The DDA is a cationic quaternary ammonium salt 
supporting the uptake and presentation of the vaccine antigens in the appropriate subset 
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of APC. The TDB is a glycolipid, further described as synthetic analog of trehalose 6,6’-
dimycolate (TDM or cord-factor)133. It activates the APC through syk-Card9 signaling 
pathway134. Being first developed within a program to improve vaccines against 
tuberculosis (TBC)135, it was also tested for HIV136,137 and malaria131. There, it showed 
not only potent immune-enhancing properties on humoral and cellular immune 
responses, but also a good safety and tolerability profile. A recent study including a 
vaccine candidate against TBC confirmed long lasting immunity135. Especially the 
elicited TH1 mediated immune response is promising for a BSV adjuvant. In direct 
comparison against Alhydrogel in a pre-clinical trial it showed superior immunogenicity 
and protection131.  
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1.3 Helminth infection in humans and their impact on malaria 
vaccines 
1.3.1 Potential factors capable of impairing vaccine efficacy and immunogenicity 
in malaria endemic areas 
Among the various challenges in vaccine development, one has to account for the special 
situation in endemic countries. Frequently, vaccine candidates are first tested for 
tolerability and immunogenicity in populations of high income and non-endemic 
countries, which can have a fundamentally different immune profile compared to the 
population in endemic countries138. Therefore, it is sometimes difficult to reproduce a 
result of efficacy trials conducted in non-endemic countries when they are conducted in 
endemic countries139–141. This particularly applies to vaccine candidates for parasitic 
diseases and has been shown in various studies; most recently, by using controlled human 
malaria infection (CHMI) to assess vaccine efficacy in both European and African study 
subjects receiving the P. falciparum sporozoite Sanaria vaccine (PfSPZ Vaccine)81.  
There are several factors that may impair the efficacy of a vaccine in endemic areas such 
as: maternal antibodies142,143, malnutrition and inadequate micronutrient intake144,145, 
immune tolerance and co-infections146–156. The impact of co-infection with helminths on 
vaccine immunogenicity will be detailed further in the following section. 
1.3.2 Epidemiology of helminths  
Helminth infections occur, inter alia, in stable endemic malaria transmission areas. The 
most ubiquitous species, which share the same spatial distribution as P. falciparum in 
sub-Saharan Africa are the soil-transmitted helminths with 1.5 billion people infected157. 
Hookworm infections occur throughout almost the whole continent, whereas Ascaris 
lumbricoides (A. lumbricoides) and Trichuris trichiura (T. trichiura) are more frequent 
in equatorial regions158,159. Other helminths such as Schistosoma are often focal 
distributed, owing to spatial heterogeneities in human behavior and the presence of 
water-bodies159,160. Around 102.3 million people were treated in 2017161. With an even 
more restricted incidence Loa loa (L. loa) infects around 10 million people in central and 
western Africa. It is mainly endemic in ten tropical countries. Gabon and Equatorial 
Guinea are high risk areas162.  
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Because of the geographical overlap between helminths and malaria, humans living in 
malaria endemic countries are usually co-infected with or exposed to helminths. This can 
have an impact on the immunogenicity and efficacy of malaria vaccine candidates. 
1.3.3 Helminths induced immune regulation and its impact on vaccine elicited 
immune response 
By comparison to other pathogens, helminths are large macro-parasites. Because of their 
long lifespan (ranging from 1 to 8 years depending on the species), helminth infection of 
the human host usually results in a chronic infection that can last years or decades if not 
treated. Parasitic helminths have developed a set of mechanisms to escape the host 
immune system. Chronic infections with helminth have been shown to induce a skewed 
TH2 immune response, which is marked by the involvement of CD4+ TH2 cells subset, 
the release of TH2-type cytokine such as IL4, IL5, IL8, IL10, and IL13, the secretion of 
IgE, and a subsequent expansion of eosinophil effector cells. Concomitant to the TH2 
type response, chronic helminth infection also lead to a dampening of the immune system 
through the involvement of Treg and the subsequent secretion of immune-suppressive 
cytokines such as Il-10 and TGF-ß163–165. Moreover, T cells may become exhausted and 
undergo apoptosis166. This induces a state of immune hypo-responsiveness that benefits 
the parasite159,167 but may also be of advantage for the human host as it prevents an 
overwhelming pro-inflammatory T helper 1 (TH1) response and subsequent organ 
damage167.  
As a disadvantage, the induced hypo-responsiveness can also affect reaction to other 
(bystander) antigens with the potential to alter vaccine induced immunogenicity167,168. 
Indeed, an effective vaccination against most bacterial and viral pathogens often requires 
a strong TH1 immune response. Impairment of vaccine-induced immunity was first 
discovered for oral vaccines such as polio146, rotavirus149,169, or cholera147,148, and 
subsequently also for vaccines administered through parenteral routes such as TBC151,153, 
tetanus155 and malaria vaccine candidates138,168,170,171. These findings suggest that an 
effective vaccine for humans living in helminth endemic areas might need a modified 
adjuvant eliciting a more TH1 polarized immune response, or the patient should be treated 
for parasitic infections before vaccination. However, more data on the impact of 
helminths infections on malaria vaccines is needed.  
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1.4 Aim of this thesis 
The aim of this thesis is to assess the safety, tolerability and immunogenicity of GMZ2 
adjuvanted with either aluminum hydroxide or CAF01 in lifelong malaria exposed 
Gabonese subjects. It reports a clinical phase I study that included CHMI to assess 
efficacy. Results of the CHMI are not reported. Moreover, as the study area is also 
endemic for helminth infection, the impact of helminth infection on GMZ2-induced 
immunogenicity is investigated.  
The main objective is to assess the tolerability profile of GMZ2-CAF01 compared to 
GMZ2-Alhydrogel and a control vaccine (rabies vaccine) by assessing the number and 
severity of local and systemic adverse events (AE), the number and severity of serious 
AEs, and the causal relationship between AE occurrence and vaccination. 
The second objective is to compare the immunogenicity of GMZ2-CAF01 against 
GMZ2-Alhydrogel by measuring the humoral response, and to assess the impact of 
helminth infection on the elicited immunogenicity.  
The third objective is an explorative analysis of the relationship between AEs and the 
magnitude of immune response.  
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2. Methods 
2.1 Study design 
The study was designed as a phase I vaccine trial entitled “A randomized, controlled, 
double-blind, single-center phase I clinical trial to evaluate the safety, tolerability, 
immunogenicity and efficacy of CAF01 and aluminum hydroxide as adjuvants for the 
malaria vaccine candidate GMZ2 in healthy adult African volunteers”. The trial protocol 
can be accessed as part of the puplication172. 
2.1.1 Study period 
The trial started with the first vaccinations on the 20th of April 2015 and ended with the 
last follow up visit on the 22th November 2015. The study period covered the end of the 
rainy season in spring, the dry season in summer and the start of the second rainy season 
in autumn.  
2.1.2 Study site 
The trial was conducted at the Centre de Recherches Médicales de Lambaréné 
(CERMEL), Gabon (figure 7). CERMEL originated out of the Medical Research Unit of 
the Albert Schweitzer Hospital, which was founded in 1981 as an integral part of the 
hospital. In 2011 the research unit was transformed into an independent non-profit 
organization and renamed into CERMEL. It has a robust track record on clinical trials 
and decades of experiences with conducting studies according to the “International 
Conference on Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use – Good Clinical Practice (GCP)” guidelines in the area 
of Lambaréné. The research activities of CERMEL include various epidemiological and 
interventional trials on tropical diseases. Amongst them studies on anti-malarial drugs 
(phase I-III), CHMI trials, studies of several malaria vaccine candidates (phase II and III) 
and, precursor GMZ2 trials (phase I and II) have been conducted.  
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Figure 7: Medical research unit (CERMEL) (left), Lambaréné173 (right) 
Lambaréné itself is a semi urban town located just below the equator in the central 
African rainforest (figure 8). It is crossed by the river Ogooué, one of the grand rivers of 
Central Africa. With a population of around 25,000 Inhabitants, it is the capital of 
Moyen-Ogooué, which is one of the nine provinces of Gabon. Gabon has a population 
of approximately 1.5 million inhabitants with 80% concentrated in the urban areas. There 
are around forty different ethnic groups. Bantu Tribes are the most common ones 
including Fang, which represents about 30% of the whole population174. 
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Figure 8: Map of Gabon from the Blue Marble collection of NASA adapted for this thesis175   
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Climate 
The average annual temperature in Lambaréné is 26.6°C, the humidity ranges between 
80 to 84% and the precipitation is of 257mm divided on two rain seasons February to 
May and October to November176,177 as shown in figure 9 and 10.  
 
Figure 9: Precipitation and humidity in Lambaréné. The light blue bars represent the 
precipitation in each month, whereas the humidity is displayed by a dark blue line176,177. 
 
 
Figure 10: Temperature in Lambaréné. The dark blue line represents the average temperature 
during the year. The light blue area displays the temperature range176,177. 
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Endemic diseases  
The area is endemic for malaria and various helminths infections. With an entomological 
inoculation rate of about 50 infective bites per person per year and little seasonal changes 
malaria is hyper endemic in Lambaréné and surroundings178,179, although incidence 
decreased over the last decades. The disease represents one of the major health problems 
of Gabon. Most infections are caused by P. falciparum (95%), whereas P. malariae and 
P. ovale play a less important role. P. vivax does not occur. The prevalence for 
parasitemia in afebrile adult males in the area of Lambaréné is 52%, 40% being 
submicroscopic malaria infections180. Severe malaria occurs nearly exclusively in 
children. At the age of 2-12 years, children experience ~ 1.5 malaria attacks per year in 
average, with a large individual variability181. Concerning anti-malarial drug resistance, 
the prevalence of chloroquine-resistant genotypes is continuously high (89%)182. 
Moreover, prevalence of the wild-type allele N86Y of the P. falciparum multidrug 
resistance 1, which is associated with decreased lumefantrine sensitivity, is 
increasing183.The predominant vectors for malaria transmissions in Lambaréné are 
Anopheles gambiae and Anopheles moucheti.  
Helminths are also highly endemic in Lambaréné and the main species are Schistosoma 
haematobium (S. haematobium), L. loa and Mansonella perstans as well as intestinal 
helminths species such as A. lumbricoides. A survey of the minister of health which 
included 418 subjects living in different villages in the in Moyen-Ogooué province 
showed a general prevalence of 10.1%, for urinary schistosomiasis, 2.4% for intestinal 
schistosomiasis and 38.5% for soil-transmitted helminths4. Furthermore the prevalence 
of filaria infections was found to be 26.4% for L. loa and 14.6% for Mansonella perstans 
184. Co-infection with both helminth and/or malaria usually start at young age with a 
prevalence of 6% in 1-5 years old children and reaches the peak of infection up to 55% 
in school-age (own unpublished data). 
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2.1.3 Study participants 
Study participants were healthy, male Gabonese adults living in Lambaréné with a life-
long exposure to malaria. The inclusion and exclusion criteria were chosen in order to 
minimize potential risks for the participants. The criteria ensure the absence of diseases 
such as blood disorders, chronic illnesses such as Hepatitis C, Hepatitis B or HIV, 
immune suppression, cardiovascular diseases or inflammation. Moreover, these 
evaluated neurological and psychiatric risk factors as well as drug abuse. Additionally, 
these criteria aimed to assess whether the participant received any other vaccine or 
investigational product in the recent past. 
Inclusion criteria 
• Healthy adults aged 18 to 40 years. 
• Able and willing (in the Investigator’s opinion) to comply with all study 
requirements. 
• Agreement to refrain from blood donation during the course of the study and after 
the end of their involvement in the study according to the local blood banking 
eligibility criteria. 
• Residence in Lambaréné or surroundings for the period of the trial. 
• History of long-term residence (>10 years) in area known to have significant 
transmission of P. falciparum. 
• Written informed consent to receive GMZ2 for immunization and PfSPZ 
Challenge for CHMI. 
• Answer all questions on the informed consent quiz correctly. 
• Willingness to take two curative anti-malarial regimens. 
• Reachable (24/7) by mobile phone during the immunization, CHMI and follow-
up. 
• A body mass index <35. 
Exclusion criteria 
• Receipt of an investigational product in the 30 days preceding enrollment, or 
planned receipt during the study period. 
• Prior receipt of an investigational malaria vaccine. 
• Immunization with more than 3 other vaccines within the past month. 
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• Any confirmed or suspected immunosuppressive or immunodeficient state, 
asplenia, recurrent, severe and chronic (more than 14 days) infections, 
immunosuppressant medication within the past 6 months (inhaled and topical 
steroids are allowed). 
• Use of immunoglobulins or blood products within 3 months prior to enrolment. 
• Sickle cell disease or any clinically relevant blood disorder. 
• Any clinically significant abnormal finding on biochemistry or hematology blood 
tests, urine analysis or clinical examination. 
• Abnormal electrocardiogram on screening: pathologic Q wave and significant 
ST-T wave changes, left ventricular hypertrophy, non-sinus rhythm except 
isolated premature atrial contractions, right of left bundle branch block, advanced 
A-V heart block (secondary or tertiary). 
• A QT/QTc interval > 450 ms. 
• History of seizure. 
• History of cancer (except basal cell carcinoma of the skin and cervical carcinoma 
in situ). 
• History of serious psychiatric condition that may affect participation in the study. 
• Any other serious chronic illness requiring hospital specialist supervision. 
• Suspected or known current alcohol abuse as defined by an alcohol intake of 
greater than 60 g per day.  
• Suspected or known injecting drug abuse in the 5 years preceding enrollment. 
• Subjects unable to be closely followed for social, geographic or psychological 
reasons. 
• A history of allergic disease or reactions likely to be exacerbated by vaccine 
administration. 
• Contraindications to the use of the first-line anti-malarial medications: 
artemether/lumefantrine or atovaquone/proguanil. 
• Positive for hepatitis B surface antigen (HBs-antigen). 
• Seropositive for hepatitis C virus (antibodies to hepatitis C virus). 
• Positive HIV test. 
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• Any other significant disease, disorder or finding which, in the opinion of the 
Investigator, may significantly increase the risk to the volunteer because of 
participation in the study, affect the ability of the volunteer to participate in the 
study or impair interpretation of the study data. 
 
2.2 Clinical procedures 
2.2.1 Informed consent procedure and Screening  
Screening of potential study participants was conducted in two steps. As a first step, local 
authorities were informed about the clinical trial and approval was obtained. Then, 
screening process was started by providing information about the study to the 
communities. This was done by experienced field workers under supervision of 
physicians.  
Interested potential participants were invited to the research facilities, where they had a 
meeting with a study physician. During this meeting the study physician explained the 
study objective and procedures in a language that was adequate for potential study 
participants. Additional questions were answered ad libidum. Participants were given a 
synopsis of the study to read at home and were re-invited the next day. 
Participants, who expressed their willingness to participate in the study, signed an 
informed consent and were screened for trial eligibility by study physicians. During the 
screening visit, a thorough clinical examination was performed along with laboratory 
analysis. The clinical examination consisted of physical examination, 
electrocardiography, measurement of blood pressure, heart frequency, temperature, and 
body weight as well as body height. For laboratory assessments blood and urine samples 
were collected to determine the liver (ALAT, ASAT, LDH) and renal function (urea, 
creatinine, urine dip stick). A blood count was also realized to determine the level of 
erythrocytes, HGB concentration, hematocrit as well as the platelet count. A total and 
differential leukocyte count was performed in search of infection markers and blood 
disorders. Suitable participants were enrolled, obtained a study identification number, 
and were listed on the screening log.  
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2.2.2 Randomization 
A computer-generated randomization list was used to allocate participants to the 
intervention groups and distributed in sealed envelopes. One of the lists was given to the 
local safety monitor to be kept in case that an emergency requires unblinding and the 
other to the vaccination formulation team. In case of a drop out of participants before the 
first vaccination, they were replaced by the next eligible participants on the screening 
log.  
2.2.3 Study vaccine  
CAF01 and aluminum hydroxide adjuvant were manufactured by Statens Serum Institut 
(SSI, Copenhagen, Denmark), whereas the lyophilized antigen (GMZ2) was provided by 
Novasep (Lyon, France). Investigational products were made according to good 
manufacturing practices. Locally purchased Verorab Rabies vaccine (Sanofi Pasteur, 
Lyon, France) served as the comparator vaccine. GMZ2 was shipped on dry ice from 
Novasep (Gosselies, Belgium) to CERMEL by World Courier Belgium n.v./s.a. 
(Zaventem, Belgium). The temperature was kept between - 20°C to -90°C as monitored 
with TempTale 4 USB (Sensitech cold chain visibility, Beverly, USA). CAF01 and 
aluminum hydroxide were shipped by Statens Serum Institut from Copenhagen to 
Libreville, where the investigational products were received by CERMEL staff and 
transferred to Lambaréné. The temperature was monitored with Libero CB loggers 
(Sensitech cold chain visibility, Buchs, Switzerland). At CERMEL the adjuvants were 
stored at 2 to 8°C until further use. At the study site, vaccine preparation was under the 
responsibilities of the vaccine manager. Vaccine preparation was done according to a 
standard operation procedure following good manufacturing practice guidelines. 
Preparation was done in a sterile flow hood and consisted in reconstitution of the 
lyophilized GMZ2 antigen with the corresponding adjuvants. The following adjuvant 
concentrations were used: 625µg DDA and 125µg TDB for each CAF01 based 
formulation and 0.85mg Al(OH)3 for each dose of aluminum-based vaccine 
formulations. GMZ2 was used at the concentration of 30µg and 100µg. After 
reconstitution three different vaccine formulation were obtained; 100µg GMZ2 + 0.85mg 
Al(OH)3, 30µg GMZ2 + 625/125µg CAF01 and 100µg GMZ2 + 625/125µg CAF01. The 
comparator vaccine was reconstituted along the instructions of the supplier. The vaccine 
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powder was reconstituted with adjuvant to obtain the respective dose in 0.5 ml. The 
vaccines were prepared on each vaccination day (0, 28, and 56), stored at 2 – 8°C in a 
fridge and used within 8 hours by intramuscular injecting in the deltoid muscle. Before 
each vaccination a symptom-directed physical examination with inspection of the 
vaccination site was performed. An advanced-life-support trained physician was present 
during the vaccination process.  
Allocation concealment was maintained by different measures. The vaccines were 
reconstituted by a pharmacist, who obtained the randomization list in a sealed envelope 
directly from the study coordinator. Administration of the vaccines was performed by 
special trained nurses in a separated vaccination room. None of these persons had any 
other responsibilities within the trial. They had no further contact to the participants, 
laboratory team or sample management. Access to the vaccination room and vaccination 
procedure was prohibited for any other member of the study team. 
2.2.4 Vaccination schedule 
Each participant received three doses of either the investigational vaccine or the 
comparator vaccine 28 days apart. Vaccine administration was done in alternating deltoid 
muscles. Depending on the vaccine formulation the study participants were split into four 
groups:  
o Group A: Comparator vaccine (Rabies)   n =  8 
o Group B: 100µg GMZ2 +0.85mg Al(OH)3  n = 12 
o Group C: 30µg GMZ2 + 625/125µg CAF01  n =  8 
o Group D: 100µg GMZ2 + 625/125µg CAF01 n = 22 
All study participants were vaccinated within 4 days. For safety concern the number of 
vaccinated subjects steadily increased from the first day (6 participants) to the fourth day 
(17 participants) as captured below. 
• Study day 0: A (n = 2), B (n = 3), C (n = 1) 
• Study day 1: A (n = 2), B (n = 3), C (n = 5), D (n = 1) 
• Study day 2: A (n = 2), B (n = 3), C (n = 1), D (n = 10) 
• Study day 3: A (n = 2), B (n = 3), C (n = 1), D (n = 11) 
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2.2.5 Follow up 
After each vaccination the participant was kept under direct surveillance for 30 minutes 
at the research facilities under close monitoring by a study physician. Participants were 
re-invited to the research facilities on day 1, 7 and 14 following each vaccination as well 
as on day 28 following the third vaccine administration. During these follow ups, they 
underwent a basic clinical examination (vital signs and tympanic temperature) and were 
interviewed to solicit AEs. On day 2, 4 and 6 post vaccination study participants were 
actively followed up at home by field workers and physicians. This aimed to ensure 
safety of the participants and collect data on solicited local and systemic AE. Moreover, 
participants were encouraged to visit the research facility and report occurrence of any 
health issue. Additionally, a 24-hour operated telephone line was available to contact the 
study team at any time. At the CERMEL a study nurse and a study physician were 
available all times. 
Blood was collected at different time points for routine analysis (day 0, 7, 14, 28, 35, 42, 
56, 63, 70, and 84) and in order to assess the humoral and cellular mediated immune 
response to the vaccine candidate (day 0 and 84). Stool samples were collected for the 
detection of helminths infections at the screening visit and at day 84. A summary of study 
procedures is given in table 2. 
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Table 2: Study procedures (* Screening visit, additional actions performed: Informed consent, full medical history, review of vaccinations, assessment 
of in/exclusion criteria, virology (HIV, Hepatitis B, Hepatitis C) **First vaccination, additional actions performed: Randomization, Assignment of 
identifier and Supply of identifier card, ***Laboratory analysis includes complete blood count, AST (Aspartate transaminase), ALT (Alanine 
transaminase), and creatinine) 
Day  SCR* 0 1 2 4 6 7 14 28 29 30 32 34 35 42 56 57 58 60 62 63 70 84 
Vaccinations  I**           II             III               
Visits at CERMEL x x x       x x x x       x x x x       x x x 
Home visits       x x x         x x x         x x x       
Adverse event review   x x x x x x x x x x x x x x x x x x x x x x 
Physical examination x  x             x             x             x 
Blood for basic laboratory 
analysis*** 
x x         x x x         x x x         x x x 
Serum for Immunology  x                                         x 
Stool and Urine for 
helminths infection 
x                                          x 
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Adverse Events 
An AE is defined by the WHO as follows: “Any untoward medical occurrence in a patient 
or clinical investigation subject administered a pharmaceutical product and which does 
not necessarily have to have a causal relationship with this treatment. An adverse event 
(AE) can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal product, whether or not considered related to the medicinal product”185. For 
marketed medicinal products the definition is extended to failure of produce expected 
benefits, abuse or misuse.  
The severity of AE was assessed with the grades depicted in table 3. For the solicited 
AEs gradings were further defined as described in table 5 and 6.  
Table 3: Grading of severity of AE 
Severity grading Explanation 
1 Mild No effect on activities of daily living 
2 Moderate Some interference with activity not requiring medical intervention 
3 Severe Prevents daily activity and requires medical intervention 
4 Life-threatening Hospitalization; immediate medical intervention or therapy 
required to prevent death. 
 
Every AE was recorded regardless of the possibility of being vaccine related. For each 
occurred AE the time of onset, outcome, intensity and relationship to the vaccine was 
evaluated and documented in the case report form. All solicited local reactions following 
vaccination were considered causally related to the vaccination.  
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The relation to the vaccine was assessed with the guidance presented in table 4. 
Table 4: Grading of relationship of adverse events to the study vaccine 
Causality grading Explanation 
1 No 
Relationship 
No temporal relationship to study product and 
alternate etiology (clinical state, environmental or other interventions); 
and does not follow known pattern of response to study product 
2 Unlikely Unlikely temporal relationship to study product and 
alternate etiology likely (clinical state, environmental or other 
interventions) and does not follow known typical or plausible pattern 
of response to study product. 
3 Possible 
  
Reasonable temporal relationship to study product; or event not 
readily produced by clinical state, environmental or other 
interventions; or similar pattern of response to that seen with other 
vaccines 
4 Probable 
  
Reasonable temporal relationship to study product; and event not 
readily produced by clinical state, environment, or other interventions 
or known pattern of response seen with other vaccines 
5 Definite 
  
Reasonable temporal relationship to study product; and event not 
readily produced by clinical state, environment, or other interventions; 
and known pattern of response seen with other vaccines 
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Solicited Adverse Events 
Solicited AEs were collected daily from the vaccination day until day 7 after each 
vaccination and on day 14 after each vaccination. In the following are lists of solicited 
AEs and their severity: 
Table 5: List of solicited local AEs and their grading of severity (* Grade 1: 2.5 – 5 cm, Grade 
2: 5.1-10 cm, Grade 3: >10 cm, Grade 4: Necrosis or exfoliative dermatitis)186 
Local Intensity  Parameter 
Pain at injection site 0 
1 
2 
3 
Absent 
Minor reaction to touch 
Moderate reaction to touch 
spontaneously painful 
Swelling at injection site * Record greatest surface diameter in mm 
Induration at injection site * Record greatest surface diameter in mm 
Erythema at injection site * Record greatest surface diameter in mm 
Contra-lateral reaction * Record greatest surface diameter in mm 
Pruritus at injection site 0 
1 
 
2 
 
3 
Absent 
Easily tolerated by the participant, causing minimal 
discomfort and not interfering with everyday 
activities 
Sufficiently discomforting to interfere with normal 
everyday activities. 
Prevents normal, everyday activities. 
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Table 6: List of solicited systemic AEs and their grading of severity 186 
Systemic Intensity  Parameter 
Fever 0 
1 
2 
3 
Tympanic temperature < 38°C 
38< and <38.5 °C 
38.5< and <39 °C 
> 39 °C 
Nausea/vomiting 0 
1 
2 
3 
Behavior as usual 
Nausea/vomiting easily tolerated 
Nausea/vomiting that interferes with normal activity 
Nausea/vomiting that prevents normal activity 
Headache 0 
1 
2 
3 
Behavior as usual 
No effect on normal activity 
Interferes with normal activity 
Prevents normal activity 
Fatigue 0 
1 
2 
3 
Behavior as usual 
Fatigue easily tolerated 
Fatigue that interferes with normal activity 
Fatigue that prevents normal activity 
Myalgia 0 
1 
2 
3 
Behavior as usual 
No effect on normal activity 
Interferes with normal activity 
Prevents normal activity 
Diarrhea 0 
1 
2 
3 
None 
With no dehydration 
With some dehydration 
With severe dehydration 
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Serious Adverse Event 
A serious AE is defined as follows: “A serious adverse event (experience) or reaction is 
any untoward medical occurrence that at any dose: 
• Results in death; 
• Is life threatening; 
• Requires inpatient hospitalization or prolongation of existing hospitalization; 
• Results in persistent or significant disability/incapacity; 
• Is a congenital anomaly/birth defect”185. 
Abnormal Laboratory values  
The toxicity scales used to define abnormal laboratory values can be found in the annex. 
They were modified from the “Vaccines Guidances - Guidance for Industry: Toxicity 
Grading Scale for Healthy Clinical Trial Adult and Adolescent Volunteers Enrolled in 
Preventive Vaccine Clinical Trials”186 published by the federal drug administration. 
Alteration was performed along a database with reference data of adult Gabonese 
subjects in order to adapt the toxicity scale to our study population. Abnormal laboratory 
findings that were considered to be clinically significant were staged and recorded as 
AEs. 
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2.3 Laboratory assessment  
2.3.1 Immunological assays: Indirect ELISA 
To assess the IgG concentration of each participant against GLURP, MSP3 and GMZ2, 
indirect enzyme-linked immunosorbent assay (ELISA) was performed as previously 
described112,121–123. ELISA is a commonly used quantitative immunoassay to assess the 
concentration of antigen-specific antibodies in serum. 
 
Figure 11: ELISA. First, the antigen of interest is coated to a microtiter plate [1]. Afterwards, 
patient serum with the antibodies of interest is added, which bind the antigen, which in turn is 
coated on the plate [2]. Next, goat anti-human antibodies conjugated to a peroxidase are used. 
They bind the participants antibodies [3]. Then, a color solution is added, which react with the 
peroxidase conjugated to the goat IgG. The peroxidase channels a change of color [4]. The 
Tetramethylbenzidine One solution turns blue. To end the reaction, sulfuric acid is added, which 
itself turns the solution into yellow [5]. The intensity of the color change is directly proportional 
to the amount of specific serum IgG bound to the antigen on the plate and can be quantified by 
a plate reader. 
Blood preparations 
For the analysis blood was drawn on day 0 and 84 
directly centrifugated and the resultant participant 
plasma was stored in the refrigerator at -80 °C. Thus, 
it was possible to analyze all samples at the same time 
and under the same conditions. This took place at the 
end of the follow up period. The list and references of 
the reagents used are given in table 14 in the annex. 
Coating antigens were prepared by diluting GMZ2 
(123μg/vial, Michael Theisen, Denmark) in 1ml H2O 
Figure 12: Participants blood 
sample in the centrifuge 
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and further diluted in Phosphate buffered saline (PBS) until a final concentration of 
0.5μg/ml. MSP3 and GLURP at a concentration of 1μg/ml and 0.5μg/ml respectively. 
The ELISA was performed in six steps as further described below: 
Coating of microtiter plates 
During this step 96 well microtiter plates were coated with 100μl per well of GMZ2, 
GLURP or MSP3 antigens. The plates were stored overnight in a fridge at 2 to 8°C to 
ensure sufficient coating. 
Washing and blocking 
The washing and blocking steps were performed the next morning. During this phase 
dilution buffer was discarded from the plates. In order to remove non-bound antigens, 
the plates were washed four times using a washing buffer. After the last wash cycle, the 
plates were gently inverted and tapped firmly on an absorbent paper to remove any 
remaining wash solution. Afterwards, every area on the plate, which was not fully coated 
with antigen, is blocked by a non-specific protein solution. Hereby, milk powder diluted 
in blocking buffer was used. This is done to prevent unspecific serum antibodies from 
binding on the microtiter plate and subsequently prevent them to interfere in the reading 
process later. The plates were then incubated with 150μl blocking buffer for one hour on 
a rocker platform at room temperature. This was followed by four subsequent washing 
procedures with washing buffer as described above. 
Incubation with sample sera and standard IgG 
As the next step, the plates were filled with positive-negative controls, standard serial 
dilution and participant’s serum as specified below. This was done in order to allow 
binding of antigen specific IgG in participants-serum to the antigens coated on the plate.  
As shown in figure 13, the first two columns of the microtiter plate were used for 
development of the standard IgG curve. Starting from a concentration of 30,000 ng/ml 
IgG, a serial dilution row was created with following concentrations: 15,000 ng/ml IgG, 
7,500 ng/ml IgG, 3750 ng/ml IgG, 1.875 ng/ml IgG, 938 ng/ml IgG, 469 ng/ml IgG, and 
235 ng/ml IgG. Further wells were used for the negative and positive controls. Pooled 
sera from semi-immune individuals of Lambaréné served as positive controls, whereas 
sera from malaria-naïve Europeans were used as the negative controls. Moreover, a few 
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wells were filled with dilution buffer, so that the standard IgG and the participant’s serum 
photo absorbance values could be adjusted later with the values of the pure dilution 
buffer. Remaining wells were filled each with the participant’s sera samples. For each 
sample six wells were used and filled with sera in decreasing concentrations. Two wells 
served as an identical pair; The first were filled with sera diluted with dilution buffer 1:2, 
the second pair diluted 1:4 and the third pair diluted 1:8. This is further illustrated in 
figure 13. As a next step the plates were incubated for two hours at room temperature, 
while the specific antibodies in the participant’s serum bound to the antigen coated on 
the microtiter plate. The higher the concentration of specific IgG in the patient serum, 
the more binding to the antigens coated to the microtiter plate.  
 
Figure 13: Example microtiter plate 
Detection 
Another four cycles of washing procedure followed the incubation. Next, 100μl of 
peroxidase-conjugated goat anti-human IgG diluted 1:65,000 with dilution buffer was 
added in each well. These anti-human antibodies bound on the antigen specific 
participant serum antibodies and the standard IgG during one hour of further incubation. 
Subsequently, antigen-antibody-antibody-peroxidase complexes were created.  
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Coloration 
Now the plates were rewashed and 100μl 
substrate solution Tetramethylbenzidine was 
added. While the plates were light protected 
incubated for 20 minutes, the colorless 
Tetramethylbenzidine-One solution was 
oxidized by the peroxidase conjugated on the 
anti-human goat antibodies. Subsequently, it 
changed its light absorption at 450nm and 
turned into blue. The reaction was stopped 
after the 20 minutes by adding 100μl of sulfuric acid (100μl 0.2M H2SO4). This ensured 
that every plate had exactly 20 minutes of incubation. Due to the adding of the sulfuric 
acid, the solution changed the color from blue to yellow (620 nm). 
Reading 
This light absorbance was read by a plate reader 
at 450 nm, 620 nm respectively. The light 
absorption density is directly proportional to the 
amount of peroxidase enzymes in each well, 
therefore proportional to the number of anti-
human goat antibodies and finally to the amount 
of specific participant serum antibodies against 
the antigen coated on each plate.  
Calculation of the standard IgG Curve 
For the calculation of the IgG standard curve, the mean between the two columns of the 
serial dilution row was calculated at each concentration. For example (A1+A2)/2 is 
calculated for the mean absorption at the concentration at 30μg/ml. The same was done 
for the decreasing concentrations in row B to H. Afterwards the mean absorption of all 
blanc wells containing dilution buffer was generated. In the example in figure 13 it was 
the mean values of G5-G12 and H5-H12. This value was inter alia used to adjust the 
means of the serial dilution row. Now, each adjusted light absorption value of the 
standard IgG dilution row could be matched with known concentrations of the standard 
Figure 14: Adding of sulfuric acid and the 
subsequent change of color 
Figure 15: Plate reader with an example 
ELISA-plate 
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IgG. With these paired values a standard curve was calculated: y = 𝑎 + 𝑏 ∗ 𝑥. Hereby, x 
represents the natural logarithm of the antibody concentration and y the logit of 
normalized light absorption values. 
Calculation of the amount of specific antibodies in participants sera sample 
In comparison with the standard IgG curve the antibody titer of each patient’s serum 
sample could now be calculated. For this procedure, the mean light absorption values of 
each concentration of the samples were calculated. As an example, the serum sample of 
the participant with the number 101 on day 0 is taken: (A5+A6)/2, (B5+B6)/2 and 
(C5+C6)/2. The mean light absorption values were adjusted with the mean value of the 
blanc wells. Afterwards the interim amount of antibodies was calculated by using the 
standard IgG curve. The solution was picked, which was closest to the OD1. Next, the 
solution was adjusted according to their concentration in the beginning. In the example 
GZC101 on day 0, the interim amount of specific antibodies of row A was multiplied by 
two, since it was diluted 1:2. Row B followed the same procedure but was multiplicated 
with four and C was multiplicated with eight.   
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2.3.2 Diagnosis of Schistosoma haematobium infection 
(S. haematobium) was detected microscopically by determination of eggs in urine. The 
method for identification consisted of two steps. In the first step 10ml of participants 
freshly collected urine were passed through a 12μm millipore Whatman filter placed on 
a filter holder. After the step of urine filtration, the filter was removed from the filter 
holder and placed on a transparent slide. The slide was then examined for the presence 
of S. haematobium eggs by microscope using the 10x objective and a closed iris 
condenser for sufficient contrast. The eggs were identified by size, shape and spine 
(figure 16). 
 
Figure 16: Passing urine through the filter (left), unattached Whatman filter (middle), egg of S. 
haematobium under 10x magnification  
2.3.3 Detection of Ancylostomatidae, Strongyloides stercoralis 
The presence of Ancylostomatidae, Strongyloides stercoralis were assessed by detection 
of larvae in the stool using the copro culture187. This method consisted of several steps: 
First, using a spatula, a small quantity of stools was transferred on a piece of aluminum 
foil. Afterwards, a sieve was pressed on the sample, so that the fecal material passed 
through. Meanwhile, a microscopy slide was wrapped in absorbent tissue and placed in 
a petri dish. A good quantity of the sieved stool was removed with a spatula and 
transferred on the tissue. Afterwards, sufficient sterile water was added the petri dish, 
such that the tissue was moisten but the stool samples was not covered (figure 17). Then, 
the petri dish was incubated for 7 days at 25°C (+-3°C). 
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Figure 17: Sieved fecal sample on aluminum and applying stool on the tissue (left),  
incubated petri dish (right) 
For the filtration process, a 12μm Millipore Whatman filter was placed on the support of 
a syringe filter holder and afterwards the holder was reassembled. Then, the syringe was 
filled with 10ml of water of the incubated petri dish and attached to the filter holder to 
pass the water through the filter. The filter was placed on a slide. The entire filter was 
examined for larvae of Ancylostomatidae, and Strongyloides stercoralis by a phase-
contrast microscope using the 10x objective and a closed iris condenser for sufficient 
contrast. Species differentiation was done by shape and size (figure 18). 
 
Figure 18: Pressing incubated water through the Whatman filter (left), Ancylostomatidae under 
10x magnification (right) 
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2.3.3 Detection of A. lumbricoides and T. trichiura  
Infection with A. lumbricoides and T. trichiura was determined by detection of eggs 
using the Kato Katz method188. For this procedure cellophane strips were soaked in 3% 
malachite green glycerol solution for at least 24 hours. The excess glycerol was drained 
before usage. A small amount of stool was transferred to a piece of aluminum foil 
followed by a screen, which was pressed on the sample for sieving.  
 
Figure 19: Items for analysis (left), sieved stool sample on aluminum (right) 
Afterwards, a template of 41.7mg (Vestergaard Frandsen SA, Aarhus, Denmark) was 
placed on a microscopy slide and a flat sided applicator stick was used to fill the hole of 
the template with the sieved sample. Subsequently, the template was carefully removed 
and the remaining stool on the slide was covered with the cellophane strip. Next, the slide 
was inverted, placed on absorbent paper, and pressed. Consequently, the sample was 
pushed against the cellophane and spread evenly. For each sample two slides were 
prepared. The prepared slides were read within 30 minutes and re-read after 24 hours. 
The entire slide was examined systematically by microscopy for intestinal helminths 
eggs using the 10x objective and a closed iris condenser for sufficient contrast. Not 
encapsulated eggs in the size of 50-65μm*20-30μm with clearly protruding plugs were 
taken for T. trichiura, whereas non-encapsulated, non-plugged, non-spined eggs in the 
size of 45-70μm * 35-45μm with a rough shell containing rough granules were diagnosed 
as A. lumbricoides. 
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Figure 20: Slides with template and stool sample (left), stool covered with cellophane strip 
(middle), egg of A. lumbricoides under 10x magnification 
2.3.4 Detection of P. falciparum: Thick blood smear 
For detection of a P. falciparum infection a TBS was 
done applying the Lambaréné method189. Ten 
microliters of blood were taken and spread on a 10x18 
mm large rectangle on a microscope slide. Next, the 
slide was dried and stained with a 20% Giemsa 
solution. After rinsing the slide, it was air-dried and 
read using a light-optical microscope. Parasites were 
counted at 1000x magnification. The parasitemia per 
microliter was calculated using the counted parasites, 
the counted high power field (HPF) and the microscope 
factor: 
𝑃𝑎𝑟𝑎𝑠𝑖𝑡𝑒𝑠
μL
=
𝑁𝑝𝑎𝑟𝑎𝑠𝑖𝑡𝑒𝑠 
𝑁𝐻𝑃𝐹 
∗ 𝑀𝑖𝑐𝑟𝑜𝑠𝑐𝑜𝑝𝑒 𝐹𝑎𝑐𝑡𝑜𝑟. 
The microscope factor represents the number of high-
power fields, which are needed to be read to examine 1 μl of blood. It is specific for each 
microscope and can be measured or calculated.  
2.3.5 Detection of Loa loa and Mansonella filarial infections: 
To assess filarial infection status of the study participants 10 ml of blood were collected 
in ethylenediaminetetraacetic acid tubes during the morning on day 0 and 84. Detection 
of microfilaria was performed following a modified Knott’s technique190. The RBCs 
within the participants blood were lysed and the blood centrifugated. Afterwards the 
sediment was transferred to a slide and examined for motile microfilariae by microscope.  
  
Figure 21: Well-earned pause of 
an exhausted student after hours 
of malaria slide reading 
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2.3.6 Hematology 
For hematology examination, an ABX Pentra 60 (Horiba, Kyoto, Japan) was used to 
assess the number of erythrocytes, the HGB concentration, the hematocrit, the platelet 
count, and the total and differential leukocyte count. 
2.3.7 Biochemistry 
Biochemistry parameters including creatinine, AST, ALAT were measured by Cobas 
Mira Plus (Roche, Basel, Schweiz).  
  
 
- 58 - 
 
2.4 Data management: 
The data generated by the study were documented on paper in the patient record form 
which represents the source document. Afterwards the information was transmitted to 
the case report form (CRP) and transcribed into a validated database (OpenClinica) 
following the Clinical Data Interchange Standards Consortium guidelines. In order to 
avoid transferring errors the data was filled in by two independent professionals. Regular 
monitoring was performed in accordance to GCP. All CRFs were verified by the clinical 
trial monitor with use of the source documents. 
2.5 Statistical analysis  
All data were analyzed with non-parametric methods using R (Version 3.5.2) and the 
packages ‘tidyverse’, ‘readxl’, ’ggpubr’, ’ggimage’, ’reshape2’, ’magrittr’, ’dunn.test’, 
‘MASS’, ‘FSA’, ‘pracma’, and ‘car’. A Wilcoxon signed-rank test was applied to 
compare continuous variables such as anti-body titers between two groups (un-paired 
test) or timepoints (e.g. day 0 against day 84, helminths infected groups against non-
infected, paired tests). If more than two groups were involved (x-fold ratio of antibody 
increase among study groups), a Kruskal-Wallis test was used. For hierarchical testing 
within the groups, the Wilcoxon signed-rank test was applied for pairwise comparisons 
in case the overall test was significant. The correlation between to continuous variables 
was analyzed applying the Spearman’s correlation test (e.g. Number of antibodies against 
number of AE). The level of significance was set at a two-tailed type I error alpha <5%. 
2.6 Sample size justification 
An appropriate Sample size was determined with regards to the primary tolerability 
immunogenicity endpoints. The further analysis of the relationship between the 
immunogenicity and the tolerability profile of the malaria candidate vaccine was 
explorative. The same applies for the analysis of the impact of helminths infection on the 
candidate vaccine immunogenicity. 
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2.7 Ethics 
Ethical approval was given in February 2015 by the “Comité National d’Ethique de la 
Recherche” in Libreville. It is a legally mandated institution by the Gabonese ministry 
of health. The study was conducted in compliance with the study protocol, the GCP, the 
Good laboratory practice (GLP) and the International Council for Harmonization of 
Technical Requirements for Pharmaceuticals for Human Use (ICH). The informed 
consent was obtained before any study procedure took place according to the current 
edition of the Declaration of Helsinki (2013). All data concerning the identification of a 
participant were treated as confidential. All analyses were done on pseudonymized data. 
The safety of participants was ensured by a local safety monitor and a scientific 
monitoring committee. If a participant fell ill or a helminth infection was detected, the 
participant was treated according the national guidelines. The trial is registered with the 
Pan-African Clinical Trials Registry, trial number PACTR201503001038304. 
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3 Results 
3.1 Study flow and baseline characteristics of the study population 
A total of 91 subjects were screened for study eligibility of whom 16 persons were not 
eligibly, mostly due to medical reasons, 6 declined to participate and 69 met all the 
inclusion criteria and none of the exclusion criteria. Of the 69 eligible individuals 50 
were enrolled in the study, randomly assigned to one of the study groups and received 
their first vaccine dose (figure 22). Before the completion of the vaccination regimen 
three study participants moved out of the study area. Two of them left after the first 
vaccination on day 7 (Group A) and 14 (Group D) respectively and the third left on day 
30 (Group A), which is after the second vaccination.  
The age of the study participants ranged from 18.1 to 37.4 as displayed in table 7. 
Demographic characteristics of the study groups such as age, body mass index (BMI), 
HGB level, the amount of white blood cells, thrombocytes and the baseline IgG titers for 
GMZ, MSP3 and GLURP were similar between groups. Helminth infection was present 
in 21 (42%) of the study participants. S. haematobium was diagnosed in 15 individuals 
(30%) and intestinal helminths affected 10 individuals (20%). Poly-infection with S. 
haematobium and intestinal helminths accounted for 5 (10%) subjects. Distribution of 
helminth infection among the study group is depicted in table 7.  
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Figure 22: Study flow diagram 
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Table 7: Baseline characteristics of vaccine groups with *median, (minimal – maximum value), 
#helminths infections at day 0 and/or day 84 (absolute numbers of infected subjects and infected 
percent) 
  Total Group A Group B Group C Group D  
(n=50) (n=8) (n=12) (n=8) (n=22) 
Age * 22.7 22.8 24.4 22.4 22 
in years (18.1-37.4) (21.8-35.5) (19.2-32.2) (20.2-35) (18.1-37.4) 
BMI* 22 22.5 22.1 21.7 22.5 
in kg/m2 (16.7-29.7) (16.7-25.3) (18.8-29.7) (19.1-23.1) (18.8-25.6) 
HGB * 13.8 14 14.5 14 13.6 
in g/dl (11.1-16.3) (12-15.3) (12.7-16.2) (11.1-15.7) (11.7-16.3) 
White blood cells* 5.2 5.7 5.1 5.2 5.1 
in cells/µl (2.7-10.1) (4.7-8.6) (2.7-10.1) (3.8-9.7) (3.1-9.1) 
Thrombocytes * 195.5 204.5 192 151.5 190 
in cells/µl (91-343) (144-258) (162-317) (91-267) (98-343) 
GMZ2 IgG* 1357.4 2025 1242.3 1240 1266.8 
ng/ml (413-5973) (1053 – 2493) (670-3916) (572-5134) (413-5973) 
MSP3 IgG* 1161.3 1630.1 1373 1112.4 1075 
ng/ml (429-12929) (547-2893) (452-3987) (429-12929) (478-12514) 
GLURP IgG* 1470.9 1252.5 1418.2 814.7 1616.5 
ng/ml (546-9162) (657-3049) (583-2582) (546-4267) (557-9162) 
General helminth 
infection # 
21 3 3 4 11 
(42%) (37.5%) (25%) (50%) (50%) 
Schistosomiasis # 15 1 2 3 9 
 (30%) (12.5%) (16.7%) (37.5%) (40.9%) 
Intestinal 
helminths # 
10 2 2 1 5 
(20%) (25%) (16.7%) (12.5%) (22.7%) 
Trichuris # 4 0 1 1 2 
 (8%)  (8.3%) (12.5%) (9.1%) 
Ascaris # 1 0 0 0 1 
 (2%)    (4.6%) 
Hookworm # 7 2 1 0 4 
 (14%) (25%) (8.3%)  (18.2%) 
Other helminths 
infections # 
3 0 0 0 3 
(6%)    (13.6%) 
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3.2 Safety and tolerability 
Regarding the analysis of safety and tolerability, the intention to treat population was 
analyzed. Thus, every participant was considered whether or whether not he completed 
the whole vaccination schedule. During the follow up period of the study from day 0 to 
day 84 no serious AE was recorded, and no participant had to be withdrawn concerning 
safety reasons. 221 AEs occurred in total, 196 being Grade 1, 25 Grade 2 and none Grade 
3. 130 of those were at least possible related to the study vaccines (115 Grade 1, 15 Grade 
2). The 15 related Grade 2 AEs were distributed on 13 participants and consisted of 14 
times injection site pain and one episode of myalgia. They were all recorded in GMZ2-
immunized participants (4 Group B, 5 Group C, 6 Group D). Two participants had no 
AE during the follow up period (1 Group A and 1 Group B). 
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3.2.1 Solicited local adverse events 
The number of local AEs went from 27 (50%) to 34 (68.8%) and 26 (55.3%) after first, 
second and third vaccination respectively as shown in figure 23. 73 were Grade 1 and 14 
were Grade 2. The most frequent AE was pain at injection side (71 Grade 1 and 14 Grade 
2) and the only Grade 2 local AEs. It occurred after 58.6% of all vaccinations. One 
swelling and 1 pruritus at injection site (Grade 1, each) was observed. Indurations, 
erythema at injection site or contra-lateral reactions were not observed.  
The rabies group showed lower AE rates (33.4% AE per dose (p.d.)) compared to the 
groups with GMZ2 formulations (60.4% p.d.), whereas the frequency among the GMZ2 
groups where similar and not dose-dependent (Group B 51 % p.d., Group C, 96% p.d., 
Group D 56% p.d., figure 23). 
 
Figure 23: Solicited local AEs recorded following vaccination. Each row represents one 
participant. Given is the Grade of the AE (highest intensity at each day of follow up) as shading 
(from light turquoise [no AE] to dark cyan [Grade 3]). Missed visits are indicated in white. 
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3.2.2 Solicited systemic adverse events 
A total number of 66 solicited systemic AEs were experienced by 31 participants. 38 of 
those were judged to be at least possible related to the study products. The amount of 
solicited related systemic AEs were 17 (24%), 10 (23%), and 11 (25.5%) following 
vaccination 1, 2 and 3 respectively. Three subjects developed a Grade 2 systemic 
solicited AE. One of them was judged to be possible related to the study vaccine. It 
occurred on day 61 (myalgia) in a subject vaccinated with 100μg GMZ2-CAF01. The 
frequency of AEs was similar among the groups as shown in table 8. 
Table 8: Rate of solicited systemic AEs (* average amount of AEs per person) 
Group Total 
(n = 50) 
A 
(n = 8) 
B 
(n = 12) 
C 
(n = 8) 
D 
(n = 22) 
Solicited systemic AE 66  
(1.38*) 
11  
(1.37*) 
18  
(1.5*) 
10  
(1.25*) 
27  
(1.22*) 
 Related to study 38 
(0.76*) 
5 
(0.63*) 
14 
(1.17*) 
7 
(0.88*) 
12 
(0.55*) 
Diarrhea 14 2 4 3 5 
Related to study 7 2 3 1 1 
Fatigue 10 2 3 2 3 
Related to study 10 2 3 2 3 
Fever 4 1 2 0 1 
Related to study 2 0 2 0 0 
Headache 23 6 2 4 11 
Related to study 10 1 2 3 4 
Myalgia 4 0 1 0 3 
Related to study 1 0 0 0 1 
Nausea 11 0 6 1 4 
Related to study 8 0 4 1 3 
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3.2.3 Unsolicited adverse events 
A total of 68 unsolicited AEs was recorded. 60 of them were mild (Grade 1) and 8 were 
moderate (Grade 2). The number of unsolicited AEs were 18 (34%), 28 (39.6%), and 22 
(34%) following vaccination 1, 2 and 3 respectively. The 5 Grade 1 unsolicited AEs, 
which were judged at least possible related to the study vaccines, were two times pruritus 
(Group B, day 28 and Group D, day 64), loss of appetite (Group C, day 0), asthenia 
(Group B, day 0), and pyuria (Group A, day 28). They were equally distributed among 
the vaccination groups as depicted in table 9. 
Table 9: Number of unsolicited AEs recorded during the vaccination period (*AE per person, 
**at least possibly related AEs) 
 Total Group A Group B Group C Group D 
Grade  I II I II I II I II I II 
All AE 60 8 7 1 16 1 12 2 25 4 
(rate*) (1.2) (0.16) (0.88) (0.13) (1.33) (0.08) (1.50) (0.25) (1.14) (0.18) 
Related AE** 5  1  2  1  1  
(rate*) (0.10)  (0.13)  (0.17)  (0.13)  (0.05)  
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3.2.4 Laboratory measurements 
Abnormal values were distributed equally among the groups as shown in table 11. Their 
severity graded from 1 to 3. No Grade 4 value occurred. The only severe laboratory 
values (Grade 3) were low thrombocytes and low neutrophils, which occurred in all 
vaccination groups. No abnormal laboratory value was judged to be clinically significant. 
The values for creatinine, leucocytes, lymphocytes, and eosinophils stayed within the 
reference limits. The figures 24 to 26 show boxplots of laboratory parameters over all 
study visits and study groups. 
Table 10: Number of volunteers with abnormal laboratory findings by parameter and grade. The 
rate of events recorded per individual is indicated into brackets. Abbreviations: HGB: 
Hemoglobin, AST: Aspartate-Aminotransferase, ALT: Alanine-Aminotransferase, Neu: 
Neutrophils, Tho: Thrombocytes 
 Grade   Total Group A Group B Group C Group D 
   (n=50) (n=8) (n=12) (n=8) (n=22) 
HGB 1 14 (28%)   1 (8%) 7 (88%) 6 (28%) 
 2 1 (2%)       1 (5%) 
NEU 1 34 (68%) 3 (38%) 8 (67%) 7 (88%) 16 (73%) 
 2 22 (44%) 1 (13%) 7 (58%) 4 (50%) 10 (45%) 
 3 11 (22%) 1 (13%) 3 (25%) 2 (25%) 5 (23%) 
THO 1 10 (20%) 1 (13%) 2 (17%) 6 (75%) 1 (5%) 
 2 8 (16%) 1 (13%)   5 (63%) 2 (9%) 
 3 5 (10%) 1 (13%) 1 (8%) 1 (13%) 2 (9%) 
ALT 1 5 (10%) 2 (25%)     3 (14%) 
 2 2 (4%)   1 (8%) 1 (13%)   
AST 1 5 (10%) 1 13%) 1 (8%) 1 (13%) 2 (9%) 
 2 2 (4%)   2 (17%)     
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Figure 24 Boxplots of HGB, leukocytes and thrombocytes for all volunteers at all visits. Dots 
represent outliers 
 
 
Figure 25: Boxplots of eosinophils, lymphocytes and neutrophils for all volunteers at all visits. 
Dots represent outliers. 
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Figure 26: Boxplots of ALT, AST and creatinine for all volunteers at all visits. Dots represent 
outliers. 
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3.3 Immunogenicity  
For the analysis of the immunogenicity the according-to-protocol study population was 
analyzed. Therefore, three participants, who did not complete their vaccination schedule 
were excluded from further analysis. 
3.3.1 GMZ2 induced immunity  
To determine the vaccine induced immunity, total anti-GMZ2 IgG as well as IgG against 
vaccine antigen subunits MSP3 and GLURP were measured before the first vaccine 
administration and on day 84. Of note: baseline level of IgG to GMZ2, MSP3, and 
GLURP were similar between the 4 different study groups (table 7 and figure 27), 
whereas the interindividual variability within the groups was rather pronounced. This 
variance converged strongly after the vaccinations on day 84 (figure 27). Vaccination 
with GMZ2 vaccine led to a significant increase of GMZ2, GLURP, and MSP3 total IgG 
in subjects who received GMZ2-Alhydrogel, 30ug GMZ2-CAF01, or 100ug GMZ2-
CAF01. In contrast, the IgG titers against GMZ2, GLURP, and MSP3 of the subjects 
who received the comparator vaccine did not differ significantly when tested by 
Wilcoxon tests (figure 27). Moreover, a comparison of the fold increase of the measured 
antibody response against GMZ2 and GLURP IgG underlined the differences among the 
study groups as significant (Kruskal Wallis, figure 28). A further exploratory analysis 
showed a significant difference between the rabies vaccine and the GMZ2 formulations 
(pooled in one group regardless of the vaccine adjuvant and dosage). However, no 
difference was observed within the different GMZ2 vaccine formulations or dosages 
(figure 29). Regarding the immunogenicity of MSP3, the hierarchical testing in figure 28 
was done exploratively, since the Kruskal Wallis was non-significant in the previous 
group testing (figure 27). 
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Figure 27: Pairwise comparison of the level of IgG against GMZ2, MSP3 and GLURP at day 0 
against day 84 with the Wilcoxon test.  
  
Figure 28: Comparison of the x-fold change of IgG against GMZ2, GLURP and MSP3 among 
the different study groups using the Kruskal-Wallis test 
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Figure 29: Pairwise comparison of different study groups. The difference is analyzed between 
a) GMZ2 and the control vaccine rabies: All subject who received GMZ2 were grouped together, 
regardless of adjuvant and dose; b) Type of adjuvant used for GMZ2 formulation: All subjects 
who received GMZCAF01 were grouped together regardless of dose; c) The dose of GMZ2: 
Significance is assessed with the Wilcoxon test. P values regarding MSP3 are explorative and 
indicated with *. 
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3.3.2 Effect of helminth infection on GMZ2 induced immunity  
Baseline assessment indicate a prevalence of helminth infection ranging from 1 to 21 of 
infected participants depending of the species (table 7). In order to assess the effect of 
helminth infection on GMZ2 vaccine induced immunity, the fold increase of total IgG to 
GMZ2, GLURP and MSP3 was compared between helminths infected and uninfected 
subjects. Due to the low number of infected subjects, all vaccine recipient of the GMZ2 
formulations were pooled together regardless of the vaccine, adjuvant and dosage. All 
subjects in the rabies group however were excluded from further analysis. As shown in 
figure 30, helminth infection resulted in a trend towards an increase to GMZ2 antibody 
in helminths infected subjects most pronounced in subjects infected by intestinal 
helminths. A comparable trend was observed for total IgG against GLURP and MSP3. 
The trend seems however to be weaker in subjects infected with S. haematobium 
compared to those with intestinal helminths.  
Further analysis was computed with the objective to determine the effect of each 
intestinal helminth species on GMZ2 vaccine immunogenicity. Hence antibody level was 
compared between subjects infected and non-infected with T. trichiura or hookworm. 
The result of the analysis is shown in figure 31. It indicates that infection with either 
intestinal helminths species led to an increase of anti-GMZ2 IgG. Unfortunately, no 
analysis could be done for the infection with A. lumbricoides due to the small number of 
infected participants (infected: n=1). The same applies for L. loa infections.  
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Figure 30: Comparison of the x-fold change of IgG against GMZ2, MSP3 and GLURP between 
helminths infected and not infected participants with the Wilcoxon test. Number of observations 
are shown in brackets. In the first column participants with any helminth infection against non-
infected are compared. The second and third columns show the s. haematobium and intestinal 
helminth infections respectively. The colors of the dots display the vaccination groups: Red = 
GMZ2-Alhydrogel, green = 30μg of GMZ2-CAF01, blue = 100μg of GMZ2-CAF01. 
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Figure 31: Comparison of the x-fold change of IgG against GMZ2, MSP3 and GLURP between 
helminths infected and non-infected participants. Number of observations is shown in brackets. 
In the first and second column the Wilcoxon test is used to compare the infected with the non-
infected groups of T. trichiura and hookworm respectively. The colors of the dots display the 
vaccination groups: Red = GMZ2-Alhydrogel, green = 30μg of GMZ2-CAF01, blue = 100μg of 
GMZ2-CAF01. 
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3.4 Relationship between adverse events and the concentration of 
elicited antibodies 
To assess the potential correlation between the vaccine-elicited inflammatory immune 
response and the occurrence of AEs an exploratory analysis was done. AEs were 
recorded from day 0 until day 84. Depending on the analysis different categories of AEs 
were created: Solely solicited AEs, every occurred AE, all AEs of severity Grade 2, 
abnormal laboratory events and severity of laboratory events. Analysis was restricted to 
participants receiving GMZ2 formulations and AE, which were at least possible related 
to the investigational product. Concerning the vaccine elicited immune response, the 
amount of antibodies against the different antigens at day 84 and the x-fold ratio of 
antibody increase were compared.  
The main finding was that no strong correlation between the immune response and AEs 
could be established. Solely for the anti-GMZ titer at day 84 a weak relationship with the 
total amount of AEs (r = 0.36) was observed. The association is stronger, if the AEs are 
restricted to Grade 2 (r = 0.43) as shown in figure 32. Anti-MSP3-titers or anti-GLURP-
titers did not show any association with AEs. The x-fold antibody increase did not show 
any correlation to the amount, severity or nature of AEs (r = 12 to r = -22). 
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 Figure 32: Correlation between AEs and vaccine induced immunogenicity. The figure is divided 
by the different antigens: a) GMZ2, b) MSP3 and c) GLURP. The first row of each subplot 
contains the antibody titer against the antigen at day 84, whereas the second row displays x-fold 
ratio of antibody change. The first column shows the comparison against total amount of solicited 
local AEs per participant, whereas the second column displays all experienced AEs, which are 
at least possible related to the study vaccines and the third row is limited to at least possible 
related AEs of Grade 2.  
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Secondly, it was assessed whether the baseline level of antibody titer may predict the 
occurrence of AEs. In order to address this question, the analysis was extended to vaccine 
specific antibodies at day 0 (analysis displayed in the annex: Figure 34 to 36). Though, 
no correlation between baseline IgG and occurrence of AEs was established either. 
Thirdly, an analysis regarding abnormal laboratory values was performed. On a primary 
approach, total amount of abnormal laboratory values and their severity were evaluated 
in correlation against vaccine specific antibodies at day 84 and the x-fold ratio of IgG 
rise. The analysis did not show strong correlations (r = -0.036 to r = 0.14) (figure 33). On 
a second approach, the analysis was extended in order to establish a potential correlation 
between trends in laboratory values and vaccine specific antibodies. Baseline corrected 
area under the curve for each laboratory value was calculated and associated with the 
IgG titer at day 84 and x-fold change (analysis displayed in the annex: Figure 37). In this 
analysis likewise no clear relationship could be depicted. Noteworthy is a weak negative 
correlation between the dynamics of HGB and the IgG values. 
 
Figure 33: Correlation between abnormal laboratory values and the vaccine induced 
Immunogenicity. The first row contains the antibody titer against GMZ2, MSP3 or GLURP at 
day 84. And the second row displays the x-fold ratio of the antibody increase. The first column 
shows the severity of abnormal laboratory values (Grade 1-3), whereas the second column 
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displays the comparison against the total amount of experienced abnormal laboratory values 
events per participant. 
In summary, no correlation between the elicited immune response and AEs could be 
established, except for a weak association between the experienced AEs and the antibody 
titer against GMZ2 at day 84. 
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4 Discussion 
Despite being a disease, which is easy to diagnose and to treat, malaria continuously 
poses a high burden to mankind. It has a heavy impact on health indicators marked by a 
loss of approximately 55 million disability-adjusted life-years191 and a mortality of 
around 435,000 (2017). Further, it constitutes a huge financial burden due to inter alia 
medical costs, reduced worker productivity and premature mortality. A country with 
falciparum transmission has a 1.3% lower economic growth rate192.  
As a result of global efforts, malaria incidence was reduced by 37% during the years 
2010 to 20154. The recent years, however, were marked by stagnation. Despite 
continuous global endeavors (US$ 3.1 billion spend in 20177), no further progress has 
been achieved in the reduction of the disease burden7. Moreover, previous achievements 
are under continuous pressure by increasing threats. These are inter alia represented by 
emerging parasite resistance to anti-malarial medicines193 and mosquito resistance to 
insecticides7. In order to accelerate and coordinate the efforts against malaria, the WHO 
designed a global strategy formulated in the “Global Technical Strategy for Malaria 
2016–2030”. Within the document the WHO defines a set of global goals to reach until 
2030. These goals include reduction of malaria morbidity and mortality rates by at least 
90%, elimination of malaria in at least 35 countries, and prevention of resurgence of 
malaria in all malaria-free countries66. To accomplish these objectives, new tools in the 
fight against malaria are needed. Of particularly value would be an anti-malaria vaccine. 
Vaccines are the most cost-effective intervention for public health72. They have been 
utilized in several previous eradication programs such as polio73, smallpox74, and 
measles75. Thus, the WHO has set the goal to develop a second generation malaria 
vaccine with protective efficacy of at least 75% over one year by 2030193. Currently, 
development of only one malaria vaccine has completed phase III: RTS,S (Mosquirix). 
It has received a positive scientific opinion from the European Medicine Agency83 and 
is currently being administered to children in a selected number of countries as part of a 
phase IV implementation study.  
Beside RTS,S, there are several other vaccine candidates. Among the BSV, the vaccine 
category of GMZ2, there are currently several candidates evaluated in clinical efficacy 
trials. AMA-1 is one of the most studied BSV antigens. It is a key protein of the 
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merozoites to invade RBC, but it is extensively polymorphic. By now, relevant efficacy 
(64%) was only shown against vaccine like strains with no significant overall reduction 
of malaria incidence106. MSP1 is a highly abundant surface protein, which is also 
essential for RBC invasion. Antibodies against MSP1 were protective in preclinical 
studies and associated with efficacy in clinical trials194. Yet, a recent phase IIb trial 
showed no protection despite of inducing a high magnitude of antibodies103. The 
combination of AMA1 and MSP1 administered in viral vectors showed little efficacy in 
a CHMI trial195. MSP3 induces high titers of cytophilic IgG1 and IgG3196 and offered 
partial protection against malaria episodes120. Another vaccine candidate, Combination 
B, consists of MSP2, RESA and MSP1. It showed 62% reduction of parasite density, 
however the protection was strain specific and no overall clinical efficacy could be 
demonstrated105.  
GMZ2 is a BSV candidate, with an excellent safety and tolerability profile102, and 
moderate efficacy. The first-in-man phase I trial in healthy malaria naive adults took 
place in Tübingen in 2006 to assess its safety, tolerability, and immunogenicity in 
humans. Since the study was successful121 and the vaccine showed a good safety and 
tolerability, the next trial moved from malaria naïve participants to semi-immune adults 
to assess whether the observed results can be reproduced in a population with lifelong 
exposure to malaria. Thus, a phase I trial was conducted in Gabon in 2007. It confirmed 
the good safety of the vaccine candidate and showed, that the pre-existing immune 
response to vaccine antigens can be boosted122. Following this trial, the clinical 
development proceeded and a phase I trial in the target population of healthy African 
children was conducted in 2008. This vaccine trial indicated that the vaccine was well 
tolerated in children from 1-5 years of age123. In order to determine the vaccine efficacy 
under natural exposure to the parasite, a large phase IIb multicenter study was conducted 
in 2010 in four countries (Gabon, Burkina Faso, Ghana, and Uganda). A total of 1849 
children were included and followed up for one year. The results of this trial confirmed 
the good tolerability of the vaccine. However, it showed a vaccine efficacy of only 13.6% 
(95% CI: 3.6%, 23%), which was statistically significant but not high enough to warrant 
further development124. Interestingly, the capability of inducing efficacy at distinct study 
sites suggested that the vaccine was pan-reactive in the sense that it may not be limited 
by strain specific immunogenicity. Moreover, a significant relationship between the 
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immunogenicity and vaccine efficacy could be established, which indicates that a more 
immunogenic GMZ2 formulation capable of eliciting higher antibody titers could 
significantly increase the overall vaccine efficacy. 
While GMZ2 has already been safely tested in clinical trials, it was always adjuvanted 
with aluminum hydroxide, which has an excellent safety record dating back almost a 
century ago128. However, the downsides of this adjuvant are the rather poor immunogenic 
features compared to more recently developed adjuvants. Several other adjuvants have 
been proposed as an alternative to aluminum hydroxide. Among them is the CAF01 
adjuvant. It is an adjuvant with potent immune- enhancing properties on humoral and 
cellular responses197. It has been successfully assessed with other vaccine candidates 
against diseases such as TBC135, HIV136, and malaria131. In preclinical GMZ2 studies 
CAF01 vaccine formulations showed superiority over aluminum adjuvanted ones108,131. 
Therefore, the question was posed whether GMZ-CAF01 may improve the GMZ2 
vaccine immunogenicity without altering the safety of the vaccine.  
To answer the question, this phase I vaccination trial including a CHMI was conducted. 
CHMI is a method to evaluate inter alia malaria vaccine candidates in early proof of 
concept clinical studies, which has recently standardized by using inoculation of 
cryopreserved sporozoites198. Standardized CHMI can be used to conduct highly 
reproducible studies in malaria-free and malaria-endemic setting to obtain first efficacy 
data within small phase I studies without the direct necessity of cost-intense phase II 
clinical studies in malaria endemic settings. Ahead of the trial already 73 volunteers had 
been infected with CHMI in controlled clinical trials by intravenous injection of 
PfSPZ199. They were well tolerated and safe. The total number of volunteers, who 
underwent different kinds of CHMI, is in the four-figure range200. The results of the 
CHMI of this trial are discussed elsewhere172. This thesis covers the immunological and 
tolerability aspects of the vaccination phase of this clinical trial. 
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4.1 Study population 
The clinical development of a new malaria vaccine normally starts with phase I trials in 
young healthy adults within a malaria naïve population. This is due to several 
considerations: First, safety aspects: A first in human trial poses less risks for the study 
subjects if conducted in a healthy naïve population, compared to the risks for a population 
already burdened with infection. Moreover, adverse events are easier and clearer 
recognized. The difference in safety conditions in distinct endemic vs non-endemic 
situations is illustrated by the vaccine candidate Na-ASP-2 against hookworms. First it 
was used and proved to be well tolerated in the USA201, but a subsequent trial in Brazil 
had to be halted due to generalized urticarial reactions202. Secondly, immunological 
aspects: The impact of the vaccine on the immune system is easier evaluated in absence 
of preformed IgG against malaria antigens. Preexisting immunological changes due to 
former infections with p. falciparum may otherwise conceal subtle effects.  
When the malaria vaccine candidate’s tolerability profile is positively validated in a 
malaria naïve study population and it elicits a robust immunological response, the clinical 
development proceeds to tolerability and immunological evaluation in a malaria endemic 
situation. There, the tolerability profile can be further analyzed under endemic 
conditions. Moreover, the question can be answered whether preexisting levels of 
immunogenicity can by further boosted by immunization and efficacy data can be 
obtained. Nevertheless, the paradigm that large phase III trials under natural exposure is 
the first stage when efficacy data can be obtained is questioned by the increased use of 
CHMI, which is likely a good surrogate for efficacy under natural exposure203,204.  
Not only regarding safety, but also from an immunological point of view, the transit from 
a non-endemic to an endemic study population can be challenging. This is demonstrated 
by several oral vaccines139–141, and especially by the PfSPZ vaccine: Reaching 80-100% 
vaccine efficacy in European or US populations80,205, the efficacy dropped to 30-50% in 
Mali206. Further factors impairing vaccine efficacy and immunogenicity in malaria 
endemic settings are outlined in section 1.3.1. 
While GMZ2-Alhydrogel followed this path of development102(p2), the combination of 
GMZ2-CAF01 started the clinical development directly in a malaria endemic setting. 
GMZ2 itself had been extensively clinically evaluated in combination with Alhydrogel102 
and CAF01 had shown a good safety and tolerability profile in combination with other 
 
- 84 - 
 
vaccines135,136. Thus, with regards to the safety, it was reasonable to conduct the trial 
directly in a malaria endemic setting.  
In terms of immunogenicity GMZ2 had already proven the ability to elicit functional 
vaccine specific antibodies123(p2). In the current study it could not only be evaluated, 
whether GMZ2-CAF01 elicits a robust IgG response, but also whether it is able to boost 
preexisting titers against vaccine specific antigens. And further, whether this boosting 
effect is superior to GMZ2-Alhydrogel. Additionally, insights form previous GMZ2 
trials indicate, that immunological data obtained during trials with semi-immune adults 
may be translated to trials in the target population (1-5 years old children)122(p2),123(p2).  
With an inoculation rate of about fifty infective bites per person per year, little seasonal 
changes178,179 and an extensive record of clinical trials Lambaréné offered ideal 
conditions conducting the first in human trial in an malaria endemic setting. We chose 
fifty young healthy men as participants with a long-term residence over ten years in the 
area of Lambaréné to ensure a sufficient history of malaria transmission. The average 
baseline anti-body titer against the different vaccine antigens was 1309 ng/ml, therefore 
an adequate exposure can be assumed. Other baseline characteristics such as age, BMI, 
laboratory values (WBC, PLT), and helminths infections were similarly distributed 
among study groups. The level of baseline IgG among the study groups as well as the 
baseline characteristics were similar.  
Participants did not benefit directly from participating in this study. However, to 
compensate for the time investments by participating in this trial, participants received 
expense allowance. Moreover, the information they gained about their general health 
status during study procedures may have a potential indirect benefit and a physician was 
available for them twenty-four hours a day during the whole study period. Furthermore, 
participants, who did not yet receive the rabies vaccine, were offered the vaccination at 
the end of the study period.  
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4.2 Safety and tolerability 
Primary aim of this study was to assess the safety and tolerability of GMZ2 adjuvanted 
with CAF01 in semi-immune adults.  
We hypothesized that GMZ2 adjuvanted with Alhydrogel would show a good tolerability 
as shown in previous trials121–124. Even though no previous data was available regarding 
the new formulation of GMZ2 adjuvanted with CAF01, we postulated an equally good 
tolerability of the new GMZ2-CAF01 vaccine formulation, based on the tolerability 
profile of other CAF01-adjuvanted vaccines.  
In this study no serious AE and no Grade 3 AE occurred. A total of 221 AEs was recorded 
of which 130 were judged to be related to the investigational medicinal product. This 
difference is common for a vaccination trial and can be explained by the fact, that 
symptoms from common disease are reported during the study period, too. To distinguish 
between vaccine caused AEs and other AEs so called solicited AE were implemented in 
addition to the need to assess the causality of any AE. Solicited AEs are known to be 
related to vaccinations. Within the solicited AEs further differentiation was done between 
local and systemic AE, which are listed in table 5 and 6 of the methods section. All local 
solicited AEs were judged to be related to the study vaccine. In contrast, the relationship 
of the systemic solicited AEs was assessed individually by the recording study physician 
on a casual grading scale ranking from 1 (no relationship) to 5 (definite relationship) 
(table 4 method section). The same method applies to non-solicited AEs. A solicited 
systemic AE is still probable to be at least possible related to the study vaccine 58% (38 
out of 66, tables 8 result section), whereas the unsolicited AEs were judged to be related 
in only 8.3% of the cases (table 9 result section). 
Regarding the tolerability of the study group vaccinated with GMZ2-Alhydrogel, data 
obtained from previous trials did not raise any safety concerns. The most reported AE 
was pain at injection side, as it is to be expected from a subunit protein-based vaccine. 
The majority of AEs were of mild to moderate severity. A few serious AEs were recorded 
in these trials, however there were all judged not to be related to the study vaccine.  
Regarding GMZCAF01, it was the first time the vaccine-adjuvant combination was 
evaluated. Therefore, no direct comparisons to former studies can be done. Nevertheless, 
CAF01 was assessed with other vaccine candidates against diseases such as TBC135, 
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HIV136, and malaria131. Similar to the results in the current study, CAF01 had shown a 
good tolerability with focus on local AEs such as pain at injection side135,207 or injection 
side movement impairment135. Systemic AEs were observed rarely 135,136,207.  
4.2.1 Solicited local adverse events 
The distribution of the solicited local AEs was quite similar throughout the first, second 
and third vaccine administration with no significant increase towards the last vaccination. 
This was observed in previous GMZ2-Alhydrogel trials, too. The majority (97%) of 
recorded AEs was pain at injection site, of which solely a minority (16%) reached Grade 
2 severity ranking. Moreover, pain at injection site was the only Grade 2 local AE.  
A similar trend was shown during GMZ2 precursor studies. Particularly throughout the 
phase II trial conducted by Sirima et al. pain at the injection site occurred with a similar 
frequency124. This is also observed from other vaccine trials where CAF01 was used as 
an adjuvant135,136,207. Moreover, a comparison of the results of the current study with data 
obtained from a phase I vaccine trial of GMZ2 was made. It was conducted by 
Mordmüller et al. in 2007 in semi-immune adults in Lambaréné and presented similarity 
in term of study design. As in the current trial, in the 2007 study the tolerability profile 
was characterized by occurrence of AEs, which were mainly mild to moderate with no 
Grade 3 AEs recorded. However, the pattern of local AEs was different. Mordmüller et 
al. observed higher frequencies of induration, erythema, pruritus, edema and local 
heat122. One possible reason for the difference in tolerability outcome between our trial 
and Mordmüller et al. is the route of vaccine administration. In the 2007 trial the vaccine 
was administered by sub-cutaneous injection122, while in the current study it was injected 
via the intramuscular (i.m.) route. Using a muscle as a depot for the vaccine lead to less 
local reaction, because subcutaneous fat tissue is more sensitive and more likely to cause 
local irritations208. This is supported by the tolerability results of the two subsequent 
GMZ2 trials phase Ib123 (2008) and IIb124 (2010). While moving forward to the target 
population (children), the vaccine application form was changed from subcutaneous to 
i.m. This led to a substantial decrease in study vaccine related AEs per participant121–124. 
Regarding the distribution over the study groups, there is a slight difference with an 
average of 33.4% AE p.d. in the rabies group compared to 60.4% AE p.d. in the group 
of subjects vaccinated with GMZ2. The variation within the different GMZ2 formulation 
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is negligible. Neither the change of the adjuvant nor the different vaccination doses seem 
to influence the good tolerability of GMZ2. 
The findings confirm the general good tolerability of protein-based subunit vaccines, 
which do not contain live components and are considered as very safe209. Previous studies 
with the single antigens GLURP and MSP3 showed a slightly different profile of 
solicited local AEs. Regarding MSP3, Hermsen et al. found a higher frequency of pain 
at injection site (55% p.d.), erythema (100% p.d.) and indurations (100% p.d.) upon 
vaccination with 100μg GLURP-Alhydrogel210. Similar in the case of GLURP, Sirima et 
al. (2009) observed an increased occurrence of pain at infection site (60% p.d.), swelling 
(64% p.d.), and induration (91% p.d.) after immunization with 30μg MSP3-LSP196. 
Moreover, their participants experienced more severe AE, namely swellings (Grade 2: 
22% p.d., Grade 3: 42% p.d.) and indurations (Grade 2: 33.3% p.d., Grade 3: 58% p.d.)23. 
These differences may be once again explained by the variation in route of 
administration. Indeed, in contrast to the current study the vaccine was administered 
subcutaneously in these studies possibly resulting in a higher rate of local AEs. Further, 
in the case of MSP3 the choice of LSP as adjuvant may have contributed to the different 
study results. 
If compared to RTS,S the leading malaria vaccine candidate, the tolerability profile is 
slightly different. RTS,S is also injected intramuscularly and induced fewer rates of pain 
at injection site (12.4% p.d.). But, it caused higher rates of erythema (3.1% p.d.) and 
swelling (9.6% p.d.)82. In contrast, the current study showed higher rates of pain at 
injection site (55% p.d.) but fewer other forms of solicited local AE: swelling (2% p.d.) 
and no erythema. During the large trials with RTS,S Grade 3 local AEs were reported82. 
However, they occurred in low frequencies, therefore our trial was not powered to detect 
rare, potentially more severe, AE. 
The tolerability profile of vaccines against Hepatitis B, which are also adjuvanted with 
Alhydrogel and are an example of very commonly used subunit vaccines, is comparable 
to our results. Frequently observed are mild local AE: pain at injection site (2-29% p.d.), 
erythema (3% p.d.) and swelling (3% p.d.)211. Only pain at injection site occurred in 
higher frequency during our study: Grade 1 in 55% p.d., and Grade 2 in 35% p.d. of 
vaccinations.  
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4.2.2 Solicited systemic adverse events 
Only 66 solicited systemic AEs were recorded during the study of which 38 were judged 
to be at least possibly related to the investigational medicinal product. In terms of 
intensity most AEs were mild and only 1 was considered moderate (day 61, myalgia, 
group D). With regard to the type of AE, headache accounted for most of the reported 
AE (7.1% p.d.), followed by fatigue (6.3% p.d. ), diarrhea and nausea (4% p.d. each), 
fever (1.6% p.d. ), and myalgia (0.8% p.d. ) (AE rates p. d., at least possibly related to 
study vaccine, only GMZ2-formulations considered). In contrast to the pattern of local 
AE, no difference was observed between the rabies and the GMZ2 formulations (table 
8). 
In contrast to our results, the former GMZ2 phase I study conducted by Mordmüller et 
al. showed higher rates of solicited systemic AE: Headache 21.7% p.d., fatigue 18.3% 
p.d., diarrhea 15% p.d., nausea 13.3% p.d., and myalgia 11.7% p.d.. Interestingly, they 
did not report any episode of fever. Nevertheless, if compared to our overall rates of 
solicited systemic AE, the variation in observed AEs remains: While our participants 
experienced a solicited systemic AE after 43.7% of all vaccinations, Mordmüller et al. 
observed a rate of 80%. For the sake of comparability only systematic AEs were taken 
in account, which were also considered to be solicited in our study: Fever, fatigue, 
headache, myalgia, nausea, and diarrhea. Considering every solicited AE reported by 
Mordmüller et al (fever, contralateral reaction, fatigue, drowsiness, malaise, headache, 
joint pain, myalgia, loss of appetite, nausea, vomiting, diarrhea, and tachycardia) the rate 
of AEs increases to 145% AE p.d. 122.  
Other difficulties occur while comparing our results to the data obtained from the GMZ2 
phase II study. This is due to the difference in the type of solicited AEs recorded during 
both studies. In the phase II study, the list of solicited systemic AEs included “loss of 
appetite” (2.1% p.d.), “drowsiness” (0.9% p.d.), and “irritability” 0.6% p.d. Drowsiness 
may be substituted with fatigue for the sake of comparability with our results. Further 
one case of “absence of appetite” (2% p.d.) was observed but recorded as an unsolicited 
AE in our study. Regarding the corresponding AE, the phase II trial showed fewer 
frequencies of fever 1.34% p.d., drowsiness 0.15% p.d., and diarrhea 0.11% p.d. 124.  
 
- 89 - 
 
Parallel to this study Sirima et al. compared GMZ2-Alhydrogel to the rabies vaccine in 
a phase II study. Compared to our findings, the frequency of solicited systemic AEs in 
their comparator group was as well lower. They observed fever 1% p.d., drowsiness 0% 
p.d., and diarrhea 0.3% p.d. Our results show similar frequencies for fever <1% p.d., but 
higher frequencies for fatigue 8.3% p.d., and diarrhea 8.3% p.d. 124. This indicates that 
the variation in tolerability pattern between Sirima et al. and our results may not be due 
to the different adjuvant (Alhydrogel vs CAF01), but due to more general factors such as 
the distinct study populations. 
In a former phase I CAF01 trial, TBC vaccine Ag85B-ESAT-6 (H1) was adjuvanted with 
CAF01. Dissel et al. found a similar frequency of AE in comparison to our results. 
Fatigue and headache occurred slightly less with 1.5% p.d. and they additionally reported 
the occurrence of pruritus 0.5% p.d., and rash 0.5% p.d. 135. These AEs were not 
considered as solicited in our study. Nevertheless, pruritus occurred two times and was 
recorded as an unsolicited AE (4% p.d.).  
In the case of RTS,S, solicited systemic AEs similar to Sirima et al. were chosen: Loss 
of appetite 11.4% p.d., drowsiness 6.6% p.d., irritability 11.5% p.d., and temperature 
31.1% p.d.. This tolerability profile is similar to our findings, apart from the high 
frequency of fever 31.1% p.d. and the occurrence of 2.5% p.d. Grade 3 temperature rise 
(cohort of children aged 5-17months at enrollment)82. The increased temperature may 
have contributed to the increased risk of febrile seizures, which was one of the major 
safety concerns raised in the context of RTS,S84.  
If compared to the commonly used subunit Hepatitis B vaccines, the most important 
solicited systemic AEs are temperature over 27.7°C (1-6% p.d.), headache (3% p.d.) and 
anaphylaxis (1.1 per 106 doses of vaccination). Apart from the anaphylaxis, which cannot 
be detected at such low frequencies in a phase I trial, also this tolerability is comparable 
to GMZ2CAF01. 
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4.2.3 Unsolicited adverse events 
From the 68 unsolicited AEs a fraction of five was considered to be related to the study 
vaccination. The five Grade 1 AEs were two times pruritus, absence of appetite, asthenia, 
and pyuria. Absence of appetite, or asthenia are candidates for systemic solicited AE82. 
They were frequently seen in other vaccine trials. Nevertheless, in our case the frequency 
was too low to recommend the implementation of these AEs in the list of solicited AEs.  
Pruritus on the other hand, as a non-local AE, is regarded as solicited in the CAF01 trial 
conducted by Dissel et al. There, it occurred after 0.5% of all vaccinations and in our 
case after 4%. Therefore, it may be recommended to implement it as solicited in future 
CAF01 trials.  
In conclusion, GMZ2CA01 was well tolerated. Its tolerability profile is similar to the 
GMZ2-Alhydrogel profiles observed in previous trials and former CAF01 studies. 
Moreover, the AE pattern is comparable to other subunit vaccines as RTS,S and Hepatitis 
B. There are minor non-significant differences since most AEs were mild. Moderate AEs 
were rare, and no serious AE or Grade 3 AE occurred. A total of 130 possibly related 
AEs was reported during the study period. 85 were pain at the injection site of which 75 
were Grade 1. Grade 1 indicates a minor reaction to touch after vaccination, the majority 
of those resolved within 48 or 72 hours. This would be a low price for a diminished 
malaria-risk. Nevertheless, this study was not powered enough to detect rare AEs and 
safety concerns may be raised during larger trials.  
4.2.4 Abnormal laboratory values 
In reference to the safety of our study participants, blood samples were routinely assessed 
for potential signs of organ damage. HGB was analyzed to detect anemia. Leucocytes, 
lymphocytes, neutrophils, and eosinophils were evaluated for abnormal findings 
regarding the immune system. ALT and AST were assessed for potential liver damage. 
Finally, creatinine was measured in case of kidney impairment.  
The abnormal laboratory values were graded from 1 to 3 with the vast majority being 
Grade 1. The amount of abnormal laboratory value was equally distributed among study 
groups and none were considered to be clinically significant.  
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Elevated liver enzymes occurred seldomly, which could be due to inter alia non-specific 
liver irritations in the course of e.g. a virus infect or alcohol consumption. Neutropenia, 
which occurred slightly more frequent, is common after vaccinations and is mostly 
transient and benign. It can occur due to concurrent viral infections or co-medication 
(antiretrovirals and antibiotics)212. Thrombocytopenia may be explained by various 
reasons, among them an enlarged spleen in the course of a malaria infection. The same 
reason might apply for the few cases of lowered HGB.  
Noteworthy is, that abnormal values were not only distributed equally among the study 
groups, but also among the various study visits including the screening visit before the 
first vaccination. Therefore, a correlation between the vaccinations and the abnormal 
laboratory values is not probable and the irregularities were more likely caused by 
common illnesses and random fluctuation. 
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4.3 Immunogenicity 
4.3.1 GMZ2 induced immunogenicity  
The second main objective of this study was to assess the antibody mediated immune 
response induced by GMZ2 adjuvanted by either aluminum or CAF01 in an adult 
population semi-immune to malaria. Our first hypothesis was that immunization with 
GMZ2 will lead to a significant increase in IgG to the vaccine antigens. Secondly, we 
postulated that adjuvating the GMZ2 antigen with CAF01 would lead to a significant 
increase of the vaccine induced immune response in comparison to the GMZ2-
Alhydrogel formulation. Thirdly, we hypothesized, that a dose of 100μg GMZ2CAF01 
would lead to a significant increase of the vaccine specific IgG in comparison to the dose 
of 30μg GMZ2CAF01. 
Our study population has a lifelong history of recurrent malaria infections; thus, a certain 
baseline level of IgG against GMZ2, MSP3 and GLURP could be anticipated. And 
consequently, the IgG-titers at day 0 and day 84 were measured to analyze the rise and 
x-fold change of the antibodies instead of the absolute antibody concentration at day 84. 
The first important finding was that the vaccination with GMZ2 led to a significant 
increase in specific IgG antibodies against MSP3, GMZ2 and GLURP - although more 
pronounced for the two later antigens.  
Similar findings were presented in the previous GMZ2 trials where a significant increase 
of anti-GMZ2 and anti-GLURP IgG were reported and were more pronounced in 
comparison to the raise of anti-MSP3 IgG titer121–124. In the phase I and phase II GMZ2 
trials conducted by Belárd et al. and by Sirima et al. respectively, the magnitude of the 
vaccine specific antibodies fold change was higher than in the current study. These 
differences can be accounted for by the difference in the study population. Indeed, in this 
study semi-immune adults were included, whereas in the phase II multi-center study and 
the phase I trial the study population was composed of children aged from 1 to 5. They 
have a shorter history of exposure to P. falciparum and their immune system presents 
different features. Repeated infections with Plasmodium spp. can lead to activation of 
immune regulatory mechanisms, which are probably more pronounced in semi immune 
adults than in children. This is further underlined by a study conducted in 2007 by 
Mordmüller et al.122. They evaluated the impact of GMZ2-Alhydrogel on semi-immune 
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Gabonese adults similar to our study design. There, a general less pronounced increase 
of vaccine specific IgG was shown in comparison to Bélard et al.123 and Sirima et al.124, 
which in turn corresponds with our results.  
The second important finding was that no difference was observed in vaccine induced 
immune response between subjects vaccinated with GMZ2-CAF01 and subjects 
vaccinated with GMZ2-Alhydrogel. In contrast to aluminum hydroxide, CAF01 was 
selected as an adjuvant for its capacity to induce a strong and long-lasting memory cell 
mediated and humoral immune response. Our results indicate that, on the contrary to 
what was expected, changing the vaccine adjuvant from aluminum hydroxide to CAF01 
did not lead to significant increase of the vaccine specific IgG response. Therefore, 
CAF01 will probably not improve GMZ2 vaccine efficacy in a significant manner in 
larger phase II or phase III trials. This finding contradicts the result of the pre-clinical 
study assessing the effect of different adjuvants on malaria vaccine. In that study, by 
comparison to Alhydrogel, CAF01 adjuvanted malaria vaccines were more 
immunogenic131. Similar findings were obtained from clinical trials on HIV136,207 and 
TBC135 trials, where CAF01 was used as an adjuvant and demonstrated potent immune 
enhancing properties. Regarding the trials for HIV and TBC, the variance in enhanced 
immune response may be explained by the different antigens used in the vaccine trials. 
Though vaccinated with the same adjuvant, the distinct vaccine antigens themselves still 
have different immunogenic properties. Moreover, our trial was the first to compare 
Alhydrogel and CAF01 head-to-head in a human trial.  
In the case of the preclinical assessment, MSP1 was used to assess the immunogenic 
properties of CAF01 in combination with a malaria vaccine candidate. Apart from the 
general difficulties transferring pre-clinical successes into clinical trials, our study 
assessed different blood-stage antigens (MSP3 and GLURP). This may also explain the 
differences in outcome. 
 
The third finding was, that a significant difference in the immune response induced by 
the two different formulations of 30ug and 100ug of GMZ2-CAF01 was not observed.  
 
In reference to the induced immunogenicity and efficacy124,172 it is unlikely, that these 
GMZ2 formulations can reach the requirements for a malaria vaccine defined by the 
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WHO. Still, it is proven that GMZ2 can elicit functional antibodies118 and that the vaccine 
efficacy increases with higher immunogenicity124. In the current study no significant 
variations regarding immunogenicity and tolerability between 30μg and 100μg GMZ2-
CAF01 occurred. Thus, a further dose escalation of either the vaccine antigens or the 
adjuvant may be needed for a sufficient immune response to the vaccine antigens. This 
is further supported by the better efficacy in high-responders in the phase IIb trial. The 
equally good tolerability regarding both dosages indicates that the dose escalations may 
be feasible in terms of tolerability.  
Another straightforward approach may be to continue the search for a more suitable 
adjuvant for GMZ2. This is as well reflected in the development of the leading malaria 
vaccine candidate RTS,S, where it was not until several modifications of the delivery 
system (Alum to AS02/AS01), that RTS,S was capable to induce a significant level of 
protection213. Apart from aluminum salt and CAF01 formulations, there are different 
several adjuvants in clinical development such as Viral vectors (RNA or DNA based), 
MPL combinations (AS01, AS02, AS04), Montanide ISA-720, saponin-based (QS21) 
adjuvants and virosomes126,214. In a mouse model GMZ2 showed strongly improved 
immunogenic properties when attached to the surface of immunopotentiating 
reconstituted influenza virosomes215,216. If further pre-clinical testing confirms the 
adequacy of this approach, a phase I clinical trial will be necessary to assess safety and 
tolerability. Taking place in malaria naïve subjects, sera samples may be utilized to assess 
the quantity of elicited vaccine specific antibodies by ELISA. Functional assays such as 
opsonic phagocytosis of merozoites and ADCI could be used to evaluate in vitro parasite 
growths inhibition. If the resulting data indicates, that a robust and long-lived protection 
may be achievable, clinical research might proceed to develop an improved GMZ2 
formulation. Nevertheless, the success of this approach is uncertain as the example of 
CAF01 demonstrates the difficulties of translating mouse models into human application 
in adjuvant research. Another example is the adjuvant GLA-LSQ, which showed superior 
immunogenicity against Alhydrogel in preclinical studies, however failed to improve the 
antibody response to PAMVAC in a phase I trial95.  
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If an improved GMZ2 formulation can be obtained it may be combined with malaria 
vaccines targeting other stages of the parasite’s life cycle217. A combination of GMZ2 
with TBS or pre-erythrocytic vaccine candidates may not only increases the benefit on 
the subject level but also reducing the transmission on the population level, and diminish 
the risk of vaccine resistances102,217. 
 
Variation in magnitude of vaccine specific baseline IgG and at day 84 
Interestingly, a large interindividual variance at day 0 was observed. This could be 
explained by exposure to different levels of malaria transmissions among the 
participants. The general environmental parameters impacting infection rates may be 
similar for our study subjects, since they were all recruited in the area of Lambaréné. 
However, the more individual factors might have varied: The household situation, 
proximity to freshwater puddles, and the usage of vector control measurements such as 
ITN.  
Further, the large interindividual variance in baseline IgG converged strongly within day 
84. This could due to predominant boosting of the immune response of the participants, 
which had a low baseline titer in contrast to less boosting of participants, who already 
had a high IgG titer from the beginning. This poses several questions: Until what limit 
can the IgG titer be boosted? Is there a ceiling effect? Do regulatory responses play a 
role? And can a BSV be efficient at medium IgG titers levels218? 
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4.3.2 Effect of helminths infection on GMZ2 induced immunity 
In areas of high malaria transmission settings, a high prevalence of helminths co-
infections can be found219. Infections with different helminths species alter the immune 
system220 and subsequently influence vaccinations141. In the current study we aimed to 
assess the effect of chronic helminths infection on GMZ2 vaccine induced immune 
response. We discovered a trend towards increased vaccine specific antibodies in the 
helminths infected study groups compared to the non-infected. The effect is weaker for 
S. haematobium and stronger and significant for intestinal helminths especially T. 
trichiura.  
Interestingly, these results contradict previous findings. Even though heterogenous 
effects regarding the impact of different helminths infections on vaccine induced 
immunity are described in the literature, overall implications lead rather to a reduced 
immune response to vaccines. Schistosomiasis can have a negative impact on the 
immune response to tetanus-toxoid221,222, Bacillus Calmette-Guerin (BCG)153, and 
hepatitis B surface antigen222. Or it has no or low impact on BCG, hepatitis B, or tetanus 
vaccinations223,224. An association of increased antibody response to an infection with 
Schistosoma, as it is witnessed in our study, is not described.  
Regarding intestinal helminths the effects are seldom evaluated on species level. For A. 
lumbricoides a negative impact on cholera vaccines induced antibodies is shown148,168,225. 
The impact of hookworms assessed in combination with other helminths results also in 
impaired vaccine responses153 or non-interference226–228. T. trichiura leads to a 
suppressed immune response in previous studies. A clinical trial of particular interest in 
this context is a former GMZ2 study conducted with a study design similar to ours168. 
Esen et al. described an impaired vaccine induced antibody response in helminths 
infected children. This is of interest, since in their study the helminths species with the 
highest impact on the induced immunogenicity was T. trichiura. It is the same species, 
which also played a predominant role in our study – solely with an opposite effect.  
There are two major differences between the study of Esen et al. and our study, which 
may have contributed to the difference in outcome. First, the study population differed: 
In the current study we included semi-immune adults, whereas in the phase I trial of Esen 
et al. the study population was composed of children aged from one to five. Their immune 
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system had much less exposure to malaria parasites and other pathogens and 
consequently reacts different upon vaccination and immunomodulation.  
Second, the selection of adjuvants: While Esen et al. evaluated GMZ2 adjuvanted with 
Alhydrogel, in our study 29 of 41 analyzed participants received a GMZ2-CAF01 
formulation. Evidence rises from pre-clinical studies, that the helminth induced TH2 bias 
and downregulation of the immune system may be overcome by the right choice of 
adjuvants. This is inter alia indicated by a study where Schistosoma-infected mice were 
vaccinated with HIV-1 immunogen either co-administered with oligodeoxynucleotides 
containing unmethylated cytosine–phosphate–guanosine immunostimulatory or with 
incomplete Freund’s adjuvant. The former was able to induce potent TH1 anti-HIV-1 
immune responses whereas the latter evoked weak TH2 marked immunogenicity
229.  
One may postulate that immunization with CAF01 (TH1 profile) adjuvanted vaccines 
induces a higher immune response in helminths infected humans in contrast to non-
helminths infected humans: Participants could had had experienced a downregulation of 
immune responses due to helminths infection and consequently could had had a lower 
response upon natural infection ahead of the study. Therefore, they could had a lower 
baseline IgG. In the course of immunization with CAF01 the immune system might have 
been re-upregulated - especially with regards to the study vaccination antigens.  
Thus, starting at a lower baseline IgG, a raise to the same IgG titers at day 84 could have 
led to a stronger effect in x-fold change of the vaccine specific IgG in the helminths 
infected group. Indeed, the mean baseline IgG of infected participants was slightly lower 
(figure 38, annex). However, the absolute concentration of IgG at day 84 was higher in 
contrast to non-infected participants (figure 39, annex).  
Therefore, the higher x-fold change of vaccine specific IgG can at best be partially 
explained by lower baseline IgG and the downregulated immune system due to helminths 
infection ahead of the study. 
 
Apart from the two major differences between the studies, there are several minor 
matters: E.g. Esen et al. analyzed the log-transformed AUC, whereas we assessed the x-
fold change of IgG titer. However, in a second analysis the baseline corrected log 
transformed AUC was also calculated in this study for the sake of comparability (data 
not shown). The overall trend was similar though less pronounced.  
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Further, one question is, how long the participants have to be infected until the helminth 
infection has an impact on the vaccine induced immunogenicity. In our study we applied 
the same method as Esen et al. and assessed the infection status at two timepoints: Day 
0 and day 84. For the analysis we allocated every participant in the infected group, when 
he was infected at day 0 and/or at day 84. Therefore, a participant, who was negative at 
the screening and got infected at the end of the study period still counted as infected. It 
could be argued, that in that case the duration of the helminth infection was not long 
enough to influence the immune response to the study vaccine.  
Thus, the influence of helminth infections on the study vaccine was re-analyzed, while 
considering solely participants infected on day 0. In consequence, the number of 
observations was lower. Two participants were diagnosed with hookworms and three 
developed schistosomiasis during the study period. They were not counted as infected in 
the second analysis. This analysis (data not shown) showed a similar trend to higher IgG 
response in the infected group, even though the effect was smaller.  
In conclusion, several explications can be considered for the discrepancy of our results 
compared to former studies. The argument of different study populations may not be 
suitable, since in former trials study populations consisting of semi-immune adults were 
present153,221,222,227. The same applies for variance in evaluated helminth species, since 
the same species were analyzed e.g. T. trichiura in the case of Esen et al., or S. 
haematobium in the case of Malhotra et al. A question of the variation in vaccine antigen 
can be diminished with regards to Esen et al. A possible partial explanation might still 
be the choice of adjuvant. However, random effects or undetected confounders could 
have also caused the difference in outcome since the study was very limited due to low 
observation numbers. 
Further research in larger trials are needed to deepen the knowledge on the effect of 
Helminths infection on vaccine induced immunity. This accounts particularly for A. 
lumbricoides and L. loa, since the study was not powered enough to analyze their 
influence. This is not only of interest for further efforts on the way to a malaria vaccine, 
but also applies to already licensed and implemented vaccines in helminth endemic areas. 
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4.4 Relationship between tolerability and immunogenicity 
There are several ways the immune reaction upon vaccination can manifest. Measuring 
the vaccine-specific antibody response is a direct approach to evaluate the immune 
response. However, adverse events may be induced by different aspects of the same 
immune reaction (e.g. local and systemic inflammatory reactions) and therefore can be 
part of the same immune response. I therefore hypothesized that a stronger immune 
reaction upon vaccination could be associated with higher antibody titer and more severe 
or higher frequencies of adverse events.   
While looking at the tolerability and immunological profile separately, no dose-
dependent variations could be demonstrated between the study groups. The association 
between the immune response and AEs that are at least possibly related to the 
investigational medicinal product did not show a robust relationship. 
There are several possible explanations: Firstly, the most important limitation of this 
analysis is the small sample size of the clinical study and the general low frequency of 
AEs within the trial. Thus, the study might not be suited for detecting subtle effects.  
Secondly, a high local or systematic inflammatory response may lead to increased local, 
or systemic AEs. However, the quality of elicited antibodies may be influenced rather 
than the amount by the intensity of the immune reaction. Depending on the signaling of 
the PRRs of APCs, different cytokines are secreted, and consequently distinct T cell 
subsets are promoted. These in turn may or may not, depending on the subset, support 
the maturation of B cells and the subsequent development of antibodies48. Thirdly, the 
inflammatory immune response that generates AEs may not influence the vaccine-
specific immune response.  
Of note, there was a weak negative correlation between the dynamics of HGB and the 
IgG at day 84 (r=-26, p = 0.0038) and the x-fold change of IgG (r=-0.26, p = 0.0046). 
This could indicate that some participants, who eventually experienced sub-clinic 
malaria infections, were naturally boosted during the study period. Thus, they might have 
lost erythrocytes due to the erythrocytic schizogony and gained vaccine specific IgG.  
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4.5 Limitations of the thesis 
Limited samples size 
This trial was designed as a phase I clinical study. This phase represents an early stage 
of clinical development and focuses mainly on basic tolerability assessment. Therefore, 
a small number of participants were investigated. Fifty study subjects are common 
sample for a phase I clinical trial. The number of study subjects is suitable to assess 
tolerability, while not putting too many participants at unnecessary risk. Three 
participants did not finish their vaccination schedule, two study subjects of the rabies 
group and one of the GMZCAF01 group, which was correctly accounted for in the 
planning of the study. Therefore, the desired minimum of 11 participants in the GMZ2-
Alhydrogel and 11 in the GMZ2CAF01 group as explained in the sample size 
justification was achieved.  
Sample size with regards to safety 
As to be expected in a phase I trial, the sample size was not suited to establish an extended 
tolerability profile for GMZ2 adjuvanted with CAF01. The number of study subjects was 
not enough to detect rare and Grade 3 AE. Larger follow up trials like the previous 
multicenter trial with 1849 participants included and over 40 reported Grade 3 AEs are 
necessary to establish a safe GMZ2-CA01 regime.  
Sample size with regards to immunogenicity 
Regarding the immunogenicity, the study was powered to detect a rather large difference 
between GMZ2 and the comparator vaccine. In contrast, it was not sufficient to detect a 
significant variation within the different GMZ2 vaccine formulations concerning 
different adjuvants and dosage. As the primary objective of this phase I trial was not to 
conduct a head to head comparison between the different vaccine formulations, further 
studies with larger sample size might be indicated to address this question. 
Sample size with regards to helminth infection 
The prevalence of helminth infection in our cohort was small, despite of the high burden 
of helminth infection in Lambaréné. Therefore, any conclusion drawn from this analysis 
has to be limited. Even though lower prevalence of helminth infection is to be expected 
in an adult population230, the methods of parasitological diagnostics in this study 
 
- 101 - 
 
comprised microscopy and culture. Therefore, low-level infections might have been 
missed. Further, species-specific analysis was only possible for T. trichiura.  
Assessment of immunogenicity only based on quantitative antibody assay 
In the search for a potential malaria vaccine, the question of a suitable immunological 
substitute is left unanswered204. Among the tests used to detect Plasmodium spp. specific 
antibody ELISA is most common. This test is applied in most of malaria vaccine trials 
such as RTS,S213, GMZ2 precursor studies121–124, and various others. Nevertheless, the 
determination of vaccine induced immunogenicity by ELISA poses certain limitations. 
ELISA is a purely quantitative method, which does not provide insight into the 
functionality of elicited IgG231. This is of particular importance since in vivo antibodies 
are competing for epitopes on the merozoite resulting in various interactions and even in 
the blockage of effective antibodies231. Thus, functional antibody tests can yield a 
different picture regarding vaccine induced immunogenicity. In the context of malaria 
vaccine development, ADCI assays have been used to assess antibody function. This 
assay was used in previous GMZ2 studies and showed that GMZ2 vaccine induced 
antibodies were functional and had broad inhibitory effect118. Although ADCI was not 
used in this study, the information yield in previous trials on the functionality of the 
GMZ2-Alhydrogel antibodies can be extended to our finding. Nevertheless, a focus on 
the humoral part of the immune system leaves the question for the cellular immune 
system unanswered. 
Another method to assess the vaccine efficacy rather directly is a CHMI. Using this 
technique, one does not rely on natural infection and large efficacy studies to obtain 
preliminary results on the vaccine induced protection. The clinical trial, which provided 
the data for this thesis, included such a CHMI. The results of this CHMI are discussed 
elsewhere172.  
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Study population 
Regarding the study population, our cohort consisted of young semi-immune male adults. 
Although the inclusion of adults is recommended for first in human trials, the data 
generated can present some bias as the vaccine is primarily intended for use in children 
below 5 years of age. Indeed, our participants had a long history of malaria transmission, 
developed semi-immunity and their immune system reacts differently upon vaccination. 
Infants have a less experienced immune system and are more likely to be malaria naïve. 
Nevertheless, phase I studies are focused on the establishment of a safe and tolerable 
vaccination regime before moving to a more vulnerable target population. Further, the 
experience gained so far in the clinical development of GMZ2 has shown that the trend 
observed in the phase I trials can be translated to a phase I study in children121–124. 
Potential malaria infection at the timepoint of vaccination 
Another interesting point is, that an active malaria infection might interfere with 
immunization. Evidence indicates an impairment of dendritic cell function upon uptake 
of hemozoin pigments (parasite waste product). Further dendritic cell suffer IL-10-
mediated apoptosis upon infection35. Consequently, antigen presentation during 
immunization may be compromised and therefore the induction of the adaptive immune 
system upon vaccination may be equally impaired. In this current study, the status of 
occult malaria infection was assessed via TBS during screening for all participants. The 
timeframe between the screening and the first vaccination was at most twenty-one days. 
A malaria infection may have occurred within this timeframe. Moreover, asymptomatic, 
submicroscopic parasitemia was not further assessed during the study period. It may have 
occurred at a later timepoint and interfered with the second or third immunization. 
Further research is needed to assess the impact of active malaria infections on 
vaccinations and whether a preventive anti-malarial treatment is beneficial before 
vaccination. It will also be important to determine the time between the treatment and 
immunization, because the impact of the infection will extend for a time even further 
after treatment. 
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4.6 Conclusions 
In the present study we showed that the vaccine candidate GMZ2 adjuvanted with CAF01 
is well tolerated and safe. The concern that the combination of GMZ2 with a more potent 
adjuvant like CAF01 might lead to an increased rate or severity of side effects was not 
confirmed.  
Furthermore, GMZ2-CAF01 formulations elicited a robust immune response, which 
however was not superior to GMZ2-Alhydrogel. Further research is needed to deepen 
our knowledge on cellular responses and antibody functions, specificity, avidity, and 
maturation.  
Helminth infection was associated with a better vaccine-specific IgG response. This 
observation is new and contradicts previous findings. Among others, it may be the result 
of a lifelong exposure to parasites in our study population. Translation of these findings 
have to be done with caution and it is recommended assessing this question in larger 
clinical trials.  
In reference to the induced vaccine efficacy and immunogenicity it is unlikely, that 
GMZ2 formulated with CAF01 can contribute to the fight against malaria. Still, it is 
proven that GMZ2 can elicit functional antibodies118 and that the vaccine efficacy 
increases with higher immunogenicity124. Thus, a different GMZ2 formulation may still 
be worth testing to improve vaccine efficacy. Among the potential adjuvant candidates 
immunopotentiating reconstituted influenza virosomes offer a promising proprietary 
vaccine platform215. An improved GMZ2 formulation may further be combined with 
other malaria vaccines (e.g. sexual, sporogonic or mosquito stage vaccines interrupting 
malaria transmission) and complement current malaria control efforts in a potential 
malaria eradication program. 
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5 Summary 
5.1 English summary 
Despite a vast reduction of incidence and mortality rates during the beginning of the 
twenty-first century, malaria continues to be a threat to mankind. Especially in the recent 
years achievements have plateaued. In 2017 approximately 219 million cases occurred, 
of which 435,000 ended fatal. The majority of deaths occur in children and pregnant 
women. Previous successes are fragile and current key tools against malaria (ITN, IRS, 
and ACT) are under constant threat from emerging resistances. Especially the increased 
report of resistance of Plasmodiumm spp. strains to anti-malarial drugs in South Asia add 
to the complexity of the situation and indicate the urgent need to improve the strategy to 
control the disease. This is endorsed by the WHO and reflected in the “Global Technical 
Strategy for Malaria 2016–2030” that recognized the urgent need and pivotal importance 
of developing a vaccine against malaria for successful control and possible eradication 
of the disease.  
Until now RTS,S, a pre-erythrocytic malaria vaccine, has been the only vaccine to 
complete phase III development. It is currently undergoing an implementation phase IV 
study in three African countries after receiving scientific approval from the EMA and the 
WHO. Beside RTS,S, several others malaria vaccine candidates are currently assessed in 
clinical trials. GMZ2 is one of these vaccines and is a recombinant fusion protein 
consisting of conserved domains of GLURP and MSP3, two asexual blood-stage antigens 
of P. falciparum. It is designed mimicking naturally acquired anti-malarial blood-stage 
immunity. Clinical development of GMZ2 adjuvanted with Alhydrogel comprises 
several phase I trials conducted with children and adults in Africa as well as a recent 
phase II multi-center and multi-country trial. This phase II trial involving 1849 
participants 12 to 60 months of age confirmed the good tolerability of the vaccine 
candidate. Even though the protection conferred by the vaccine was modest, it has 
demonstrated that the vaccine efficacy may be increased by improving the vaccine 
immunogenicity. A straight-forward approach is to modify the adjuvant in order to 
enhance the immunogenicity with the final aim to increase the overall vaccine efficacy. 
CAF01 is a novel liposomal adjuvant system inducing a robust and long lived humoral 
and cellular immune response characterized by a TH1 profile. Pre-clinical head-to-head 
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comparison of CAF01 with Alhydrogel proved its superiority in immune enhancing 
properties. 
The current study was designed to assess tolerability and immunogenicity of GMZ2-
CAF01, as a new formulation of the GMZ2 vaccine candidate. In addition, the impact of 
helminth infection on vaccine induced immune response was determined. The study was 
designed as a randomized, double blind, single-center phase I clinical trial conducted in 
Lambaréné, Gabon. Fifty healthy young males with an history of at least 10 years of 
malaria transmission were recruited and allocated to 4 different study arms: A (Rabies, 
as comparator vaccine; n = 8), B (100μg GMZ2-Alhydrogel; n = 12), C (30µg GMZ2-
CAF01; n = 8), and D (100µg GMZ2-CAF01; n = 22). The participants were vaccinated 
on D0, D28, and D56 i.m. in alternating deltoid muscles. Safety and tolerability were 
assessed during the follow up with non-leading questions, symptom focused clinical 
examination and recurrent laboratory analysis. Immunogenicity was examined through 
the altitude of vaccine specific immunoglobulin titers measured with ELISA. Helminth 
infection status was evaluated by analyzing stool and blood samples at screening and on 
day 84.  
We confirmed that the vaccine candidate GMZ2 adjuvanted with CAF01 is well tolerated 
and safe. No serious or Grade 3 AE occurred. The predominant number of AEs was mild 
and pain at infection site. Safety signals were equivalent among study groups and GMZ2 
formulations. Regarding the immunogenicity, GMZ2-CAF01 formulations elicited a 
robust immune response, which however was not superior to GMZ2-Alhydrogel.  
Interestingly, helminth infection positively affected the altitude of vaccine specific IgG. 
This contradicts previous findings. So far, depending on the helminth species, rather 
negative implications were demonstrated if helminths infections were present during 
vaccination. Particularly, a GMZ2 precursor trial, conducted by Esen et al. reported 
reduced immune response in the presence of T. trichiura. Reasons for the differences in 
immunogenicity outcome may be the distinct study populations, since Esen et al. 
assessed the immune response in children, whereas this study worked with semi-immune 
adult subjects. Moreover, any conclusions drawn from these results is limited by the low 
observation numbers. To evaluate these effects further, larger clinical trials are 
recommended.  
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In reference to the induced vaccine efficacy and immunogenicity it is unlikely, that 
GMZ2 formulated with Alhydrogel or CAF01 can contribute to the fight against malaria. 
Still, it is proven that GMZ2 can elicit functional antibodies and that the vaccine efficacy 
increases with higher immunogenicity. Thus, a different GMZ2 formulation may still 
induce a sufficient vaccine efficacy. Among the potential adjuvant candidates 
immunopotentiating reconstituted influenza virosomes offer a promising proprietary 
vaccine platform. An improved GMZ2 formulation may further be combined with other 
malaria vaccines (e.g. sexual, sporogonic or mosquito stage vaccines interrupting malaria 
transmission) and complement current malaria control efforts in a potential malaria 
eradication program. 
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5.2 German summary 
Trotz des Rückgangs der Inzidenz und Mortalität zu Beginn des einundzwanzigsten 
Jahrhunderts stellt Malaria immer noch eine der größten Bedrohungen der Menschheit 
dar. Gerade in den letzten fünf Jahren stagnierten die Erfolge im Kampf gegen die 
Malaria. 2017 wurden immer noch circa 219 Millionen Krankheitsfälle verzeichnet von 
denen 435.000 tödlich endeten. Besonders vulnerable Gruppen sind hierbei Kinder und 
Schwangere. Die bisherigen wichtigsten Maßnahmen gegen Malaria (Insektizid 
imprägnierte Moskitobettnetze, Versprühen von Insektiziden in Innenräumen und 
Artemisinin Kombinationstherapien) sind durch aufkommende Insektizid- und 
Medikamentenresistenzen bedroht. Besonders die vermehrten Berichte über 
Artemisininresistenzen in Süd-Ost-Asien unterstreichen die Notwendigkeit neue 
Möglichkeiten in der Malariabekämpfung zu erforschen. Dies spiegelt sich auch in der 
globalen technischen Strategie gegen Malaria wider, welche von der 
Weltgesundheitsorganisation (WHO) veröffentlich wurde. Dort wird auf die Wichtigkeit 
eines Malariaimpfstoffes hingewiesen, um die Reduktion und die potentielle Eradikation 
von Malaria zu ermöglichen.  
Bislang hat nur ein Impfstoffkandidat (Mosquirix) die dritte Phase der klinischen 
Erprobung abgeschlossen. Der Impfstoff wird zurzeit in einer Phase IV 
Implementierungsstudie in drei Afrikanischen Ländern getestet, nachdem er 
Befürwortung durch EMA und WHO erlangt hatte. Neben diesem führenden Malaria 
Impfstoffkandidaten befinden sich weitere in der klinischen Erprobung. GMZ2 ist einer 
von diesen und besteht aus einem rekombinanten Fusionsprotein der konservativen 
Regionen des Glutamat Rich Protein (GLURP) und des Merozoite Surface Protein 3 
(MSP3). Diese sind zwei Antigene von P. falciparum welche primär während der 
erythrozytären Schizogony exprimiert werden. Der Impfstoff zielt darauf ab, die 
Vermehrung des Erregers im Blut zu kontrollieren und somit klinische Symptome zu 
verhindern oder zu mildern. GMZ2 wurde zusammen mit Alhydrogel als Adjuvant 
bereits in drei Phase I Studien unter anderem in semi-immunen Erwachsenen und 
Kindern in Sub-Sahara Afrika getestet. Zusätzlich wurde 2010 eine multizentrale Phase 
II Studie mit 1849 zwölf bis sechzig Monate alten Kindern durchgeführt. Auch wenn die 
Studie das gute Sicherheitsprofil des Impfstoffes bestätigen konnte, so war doch die 
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Impfwirksamkeit mit 13,6% nicht zufriedenstellend. Aber es wurde ein Zusammenhang 
zwischen Immunogenität und der Wirksamkeit hergestellt. Dadurch ergibt sich die 
Vermutung, dass eine Steigerung der Immunogenität auch eine Verbesserung der 
Wirksamkeit bedeutet. Eine Möglichkeit diese Steigerung durchzuführen ist durch die 
Auswahl eines stärkeren Adjuvanten. CAF01 ist ein potentes liposomales Adjuvant 
System, welches sowohl humoral wie auch zellulär eine langlebige Immunantwort 
auslöst. Besonders die TH1 betonte Immunreaktion ist für einen Malariaimpfstoff 
wertvoll. Darüber hinaus zeigte CAF01 in einem direkten präklinischen Vergleich eine 
dem Aluminium überlegene Immunogenität.  
Diese Dissertation basiert auf einer randomisierten Phase I Doppelblindstudie, welche 
durchgeführt worden ist, um die Sicherheit und Immunogenität von GMZ2 in 
Kombination mit CAF01 zu erfassen. Zusätzlich wurden die Auswirkungen von 
parasitären Konfektionen auf die Impfantwort untersucht. Für die Studie wurden 50 
semi-immune männliche Erwachsene aus Lambaréné (Gabun) eingeschlossen und in vier 
Gruppen eingeteilt: A (Tollwutimpfstoff als Kontrollgruppe; n = 8), B (100μg GMZ2-
Alhydrogel; n = 12), C (30µg GMZ2-CAF01; n = 8), und D (100µg GMZ2-CAF01; n = 
22). Die Teilnehmer wurden am Tag 0, 28 und 56 in den Musculus deltoideus geimpft. 
Das Sicherheitsprofil wurde durch nicht suggestive Fragen, symptomorientierte klinische 
Untersuchungen und wiederholte Laboruntersuchungen erfasst. Zur Immunogenität 
wurden die Kozentrationen der impfstoffspezifischen Immunglobuline mittels ELISA 
untersucht. Ko-infektionen wurden durch Blut und Stuhlproben während des Screenings 
und am Tag 84 bestimmt.  
Wir bestätigen, dass GMZ2-CAF01 sicher und verträglich ist. In der Studie ist weder ein 
schwerwiegendes unerwünschtes Ereignis aufgetreten, noch eines vom Schweregrad III. 
Der vorherrschende Teil der unerwünschten Ereignisse waren von mildem Schweregrad 
mit Fokus auf Schmerzen an der Einstichstelle. Das Sicherheitsprofil war vergleichbar 
zwischen den Studiengruppen. Durch die Impfung wurde eine Steigerung der 
impfstoffspezifischen Antikörper erzielt. Jedoch war die Immunantwort auf GMZ2-
CAF01 nicht signifikant größer als die GMZ-Alhydrogel induzierte Antwort. 
Interessanterweise wirkten sich die parasitären Ko-infektionen positiv auf die 
Immunogenität des Impfstoffes aus. Dies steht im Widerspruch zu der bisherigen 
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Forschung. Im Besonderen zeigte eine direkte Vorläuferstudie verminderte 
impfstoffspezifischen Antikörper in der Gegenwart von T. trichiura nach Impfung von 
GMZ2-Alhydrogel. Ein möglicher Grund für die unterschiedlichen Resultate können die 
unterschiedlichen Studienpopulationen sein. Während wir semi-immune Erwachsene 
impften, so wurde im Falle von Esen et al. der Impfstoff Kindern verabreicht. Zusätzlich 
limitiert die geringe Anzahl von Probanden die möglichen Schlüsse. Weitere, größere 
Studien sind nötig, um den Effekt von Konfektionen auf Malaria Impfstoffkandidaten zu 
untersuchen.  
Im Hinblick auf die induzierte Immunantwort ist es unwahrscheinlich, das GMZ-CAF01 
in seiner jetzigen Form einen Beitrag zum Kampf gegen Malaria leisten kann. Dennoch 
wurde in früheren Studien gezeigt, dass eine erhöhte Immunogenität auch zu einer 
besseren Wirksamkeit führen kann. Daher könnte sich GMZ2 in einer anderen 
Formulierung, wie zum Beispiel einem wirksameren Adjuvanten, immer noch als 
wertvoll erweisen. Unter den potentiellen Adjuvantsystemen stellen rekonstituierte 
Influenzavirosomen eine vielversprechende Kombinationsmöglichkeit dar.  
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11. Appendix: 
Table 11: Toxicity scale for laboratory values, adapted from FDA Center for Biologics 
Evaluation and Research. Vaccines Guidances - Guidance for Industry186 
Parameter Unit Ref. interval Severity of abnormality 
  lower upper Grade 1 Grade 2 Grade 3 Grade 4 
HGB g/dL 12 16 10.5 8.5 6.5 <6.5 
Leucocytes /nL 4 9.5 15 20 25 >25.0 
    2.5 1.5 1 <1.0 
Thrombocytes /nL 150 450 125 100 25 <25 
Neutrophils /nL 1.6 7.6 1.3 1 0.5 <0.5 
Eosinophils /nL 0.04 4.9 9 15 >15 "hyper-
eosinophilia" 
Lymphocytes /nL 0.8 4.3 0.65 0.5 0.25 <0.25 
Creatinine mg/dL 
 
1.1 1.7 2 2.5 >2.5 
ALT U/L 
 
50 125 255 500 >10 
AST U/L 
 
50 125 255 500 >10 
Table 12: Composition of buffers for the ELISA 
1-liter washing buffer  
2 PBS tablets Gibco cat # 18912-014 
1ml Tween 20 TMB ONE, KEM EN TEC cat # 4380 
29 gr. NaCL Merck cat # 1.06404.1000 
1 l. H2O  
1-liter blocking buffer  
2 PBS tablets Gibco cat # 18912-014 
1ml Tween 20 TMB ONE, KEM EN TEC cat # 4380 
30 gr. milk powder Merck cat # 1.06404.1000 
1 l. H2O  
1-liter dilution buffer  
2 PBS tablets Gibco cat # 18912-014 
1ml Tween 20 TMB ONE, KEM EN TEC cat # 4380 
10 gr. milk powder Merck cat # 1.06404.1000 
1 l. H2O  
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Table 13: List of materials 
ELISA   
Tween 20 Sigma, USA 
TMB ONE KEM EN TEC, Denmark 
Phosphate buffered saline tablets Thermo Fisher Scientific (Gibco), USA 
Naturaflor ®, dry skimmed non-fat milk Töpfer, Dietmannsried 
NaCl Merck, Darmstadt 
Peroxidase conjugated goat  
anti-human IgG 
Thermo Fisher Scientific (Invitrogen), USA 
Purified human polyclonal IgG (Standard) Binding site (is not available anymore) 
Positive serum samples Serum pool of semi-immune participants of 
former GMZ2 trials 
Negative serum samples Malaria naïve European blood samples 
GMZ2 final concentration 0.5µg/ml 
GLURP final concentration 0.5µg/ml  
MSP3 final concentration 1µg/ml  
Michael Theisen, Denmark 
Nunc-Immuno 96 MicroWell solid plates Merck, Darmstadt 
Corning® Multipette® 12-pette Merck, Darmstadt 
H2SO4 Thermo Fisher Scientific (Invitrogen), USA 
Anti-human IgG, 0.5µg/ml Sigma, USA  
Parasitological assessment  
Whatman12μm (Ø 25 mm, 12μm pore size)  Merck, Darmstadt 
Laboratory kit for the Kato-Katz method Sterlitech Cooperation, USA 
Sieve  Screen, stainless steel 60-125 mesh 
3% Malachite green oxalate solution Merck, Darmstadt 
Template of 41.7mg Vestergaard Frandsen SA, Aarhus, Denmark 
TBS  
Giemsa stain, pH 6.9solution Sigma, USA 
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Adverse events and their correlation to elicited Antibodies 
 
Figure 34: Correlation between AEs and antibodies against GMZ2. 
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Figure 35: Correlation between AEs and antibodies against MSP3 
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Figure 36: Correlation between AEs and antibodies against GLURP. 
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Laboratory values and their correlation to elicited antibodies 
 
Figure 37: Correlation between trends of laboratory values and vaccine induced 
immunogenicity. 
  
 
 
- 135 - 
 
Vaccine specific antibodies of helminth infection groups D0 and D84 
 
Figure 38: Comparison of the amount of IgG against GMZ2, MSP3 and GLURP at day 0. The 
colors of the dots display the vaccination groups: Red = GMZ2-Alhydrogel, green = 30μg of 
GMZ2-CAF01, blue = 100μg of GMZ2-CAF01. 
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Figure 39: Comparison of the amount of IgG against GMZ2, MSP3 and GLURP at day 84.  The 
colors of the dots display the vaccination groups: Red = GMZ2-Alhydrogel, green = 30μg of 
GMZ2-CAF01, blue = 100μg of GMZ2-CAF01. 
